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Biosafety: evaluation and regulation of genetically 
PRGL¿HG*0FURSVLQWKH8QLWHG6WDWHV
Richard E. Goodman
Food Allergy Research and Resource Program,Dept. of Food Science and Technology,University of 
Nebraska-Lincoln,143  Food Industry Complex,Lincoln, NE 68583-0955, USA
Abstract  This review of the safety assessment of genetically modified (GM) crops is focused primarily on the 
process and progress in the United States (US).  It reviews the development of the safety evaluation process from the 
Asilomar conference in 1975 considering issues relevant to recombinant DNA technology, to discussions between the 
86JRYHUQPHQWDFDGHPLFDQGLQGXVWULDOVFLHQWLVWVEHWZHHQDQGZKHQWKH¿UVW*0FURSVZHUHEHLQJ¿HOG
tested and evaluated commercial release for food and feed production.   International guidelines were also reviewed 
for consistency with the US system.  The overall process includes consideration of information relating to history of 
safe or unsafe human and exposure to the gene source and expressed proteins.  The primary considerations of safety for 
dietary proteins are whether or not some consumers are sensitized and have IgE antibodies against the protein encoded 
by the transgene or whether the transgene represents a risk of eliciting celiac disease.  The process considers potential 
toxic effects of expressed proteins as well as potential impacts on human and animal nutrition.  The process in the US is 
FRQVLVWHQWZLWK&RGH[$OLPHQWDULXVUHFRPPHQGDWLRQV,WIROORZVDVFLHQFHEDVHGSURFHVVEDVHGRQMXVWL¿DEOHK\SRWKHVHV
To date there is no evidence that GM crops approved in the US have harmed human or animal consumers. The evaluation 
takes into account genetic and environmental variation in products produced by plant varieties and is intended to maintain 
the standard that foods developed from GM plants are intended to be as safe as non-GM genetically similar varieties.
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1  Introduction
7KHVDIHW\RIIRRGVSURGXFHGIURPJHQHWLFDOO\PRGL¿HG
(GM) organisms, GMOs or GM crops is mandated 
by most countries including the US, China and 
countries who are members of the Codex Alimentarius 
Commission, an international food standards program 
within the World Health Organization and the Food 
and Agricultural Organization of the United Nations 
(www.codexalimentarius.org). The Codex includes 185 
member countries plus the European Union (EU) and 
KDVRI¿FLDOREVHUYHUVQRQPHPEHUFRXQWULHVSOXV
non-governmental organizations (NGOs) and outlines 
guidelines for many important questions regarding food 
safety and international trade.
The overall process of evaluating the safety of foods 
produced from GMOs has been described in only a 
few documents.  The primary food safety guidance for 
developers and regulators of GMOs is the combined 
documents of the Codex Alimentarius Commission, 
Second edition, “Foods Derived from Modern 
Biotechnology”[1]. The principles are outlined in the 
¿UVWFKDSWHU&$&*/DQGLQFOXGHGH¿QLWLRQV
of organisms derived from “Modern biotechnology”, 
or genetic modification and the risk assessment 
process that is intended to identify any new hazard 
or nutritional or safety concern presented by the new 
GM organism as well as risk management procedures 
if appropriate. Three major sections follow that are 
LQWHQGHGWRGH¿QHSURFHVVHVWRHYDOXDWHWKHVDIHW\DQG
nutritional properties of GM plants, GM animals and 
GM microbes.  The assessment strategies are quite 
similar for all three. The food allergy assessment is 
outlined as a separate annex at the end of the chapters. 
Evaluation of potential risks of toxicity, celiac disease 
and nutritional equivalence are discussed in the section 
on substantial equivalence toward the front of each of 
the documents. The Codex[1] document is a guideline 
for individual countries that have to develop their own 
regulations.  The intent of Codex is the signatory parties 
should develop regulations that are consistent with 
these guidelines unless differences are scientifically 
MXVWL¿HG6LQFHWKHGRFXPHQWVZHUHZULWWHQIURP
2003, there have been some advances in the science 
Journal of Huazhong Agricultural University Vol. 33  No.6  Oct.  2014
86 Journal of Huazhong Agricultural University Vol. 33
and those will be discussed along with commonalities. 
Newer evaluation steps will be discussed here.  This 
paper will focus primarily on the assessment as 
performed in the US.  However a review of some of 
the concerns and criticisms of people and organizations 
who opposed GMOs will also be discussed as it is 
important to understand whether there are legitimate 
safety issues that are not being addressed by regulatory 
bodies and developers.
The safety of foods derived from GMOs is a focus 
of some NGOs including Greenpeace, Friends of 
the Earth, Union of Concerned Scientists as well as 
personalities on popular television and the internet 
in the United States (US), European Union (EU) 
and China.  We must recognize that it is natural for 
consumers to be concerned about food safety, especially 
regarding new foods or technologies that many 
individuals do not fully understand.  Most consumers 
do not understand the scientific basis of allergens 
and allergies, toxins, nutrients and anti-nutrients in 
foods.  Most consumers also do not understand the 
importance of genetic diversity in food crops to enable 
production in diverse environmental conditions[2]. 
Many consumers believe that all soybeans are identical 
XQOHVVWKH\KDYHEHHQPRGL¿HGE\JHQHWLFHQJLQHHULQJ
Scientists in other disciplines also do not understand 
the tremendous variation and complexity in the normal 
composition of proteins, oils, carbohydrates and 
metabolites of all food crops.  A major focus of plant 
breeders is to introduce variation and if we consider 
the principles of genetic engineering and look closely 
at the changes, it is clear biotechnology introduces 
minimal uncertainty compared to the natural or induced 
mutations that breeders have relied upon to develop 
useful new varieties[2].  Can we explain realistic risks 
to consumers and also explain how the current safety 
assessment process minimizes risk? 
An important concern that is often voiced by the 
opponents of GM crops and of the pharmaceutical 
industry is that the companies developing the products 
are the ones who test for safety. That concern seems 
reasonable, but needs to be considered in the context 
the entire legal framework, governmental and economic 
structure of each country. Scientists in the government 
of the US and many other countries do not perform 
safety testing for most products.  It is worth noting 
that no government in the world has enough scientists 
with the right expertise or enough money to perform 
the appropriate safety tests for all potential products 
in a reasonable amount of time. Development of many 
important products would stop if developers had to wait 
for safety testing by their governments.  The regulatory 
systems established by most, including the US is to 
have a number of quality scientists in the regulatory 
departments who can review safety data critically and 
make decisions based on protocols and guidelines. 
Governments like the US have legal mechanisms for 
consultations with academic experts to assist in the 
evaluations.  The regulators also should have the ability 
WRHI¿FLHQWO\FRPPXQLFDWHZLWKGHYHORSHUVWRDVNIRU
additional data or tell them what additional tests or 
questions must be answered to gain approvals. 
I am most familiar with Monsanto as a major GM 
crop developer.  They have approximately 600 college 
educated (BS, MS and PhD) individuals working 
in the regulatory division of the company. These 
scientists plan and conduct safety and environmental 
studies, archive and characterize test substances 
(plants, seeds, DNA constructs and proteins), perform 
tests, analyze data and write reports for submission 
to regulatory agencies. They have to grow plants 
in different environments and sometimes multiple 
countries in order to perform field and environmental 
tests. The regulatory process is extremely complex 
even for one product and development and regulatory 
approvals for each product often takes ten to fourteen 
years.  Companies like Monsanto also have separate 
quality assurance units (QAU) that report to a different 
management team from the development and sales 
divisions.  The QAU reviews protocols prior to study 
conduct and audit data and reports before they are 
submitted to regulators to ensure study adequacy and 
accuracy. Their scientists evaluate mountains of data 
and develop the dossiers that are submitted to multiple 
governments before a product is allowed to be grown 
commercially. Most will gain approvals in major 
trading countries (Australia, Canada, China, Japan, 
Korea, the US and Taiwan) before releasing seeds of 
a new GM product to farmers. International trade of 
commodities and foods and feed will only work if 
the developer is managing materials and data as they 
have the capacity and incentive to ensure timely and 
coordinated processes.  In some cases regulatory studies 
are performed by contract laboratories, especially 
toxicology studies as there are regulations that are 
very strict that require specific tests to be performed 
IROORZLQJ ³*RRG/DERUDWRU\3UDFWLFHV´ */3 DV
defined by the Environmental Protection Agency 
(EPA) of the US government. Few developers have 
WKHLQIUDVWUXFWXUHWRPHHWDOO*/3UHTXLUHPHQWV 7KH
toxicology contract companies specialize in meeting 
regulatory demands. Those studies can be audited by 
5LFKDUG(*RRGPDQ%LRVDIHW\HYDOXDWLRQDQGUHJXODWLRQRI*HQHWLFDOO\0RGL¿HG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EPA.  There are strict rules about record keeping, ethics 
and integrity of data.  It might be important to consider 
that if the government were to perform those studies, 
who would audit them and hold them accountable?  
Some s tud ies  a re  pe r fo rmed  by  academic 
laboratories because neither the developer nor any 
FRQWUDFW*/3 ODERUDWRU\KDV WKH ULJKW H[SHUWLVH WR
perform the study.  My laboratory at the University 
of Nebraska has performed a number of allergenicity 
studies (human serum IgE binding and bioinformatics 
studies) for biotech companies and non-profit 
agricultural organizations as well as food companies 
developing novel ingredients.  We have collaborations 
ZLWKFOLQLFLDQVZKRDUUDQJHVDPSOHVIURPVSHFL¿FDOO\
allergic patients who are willing to contribute serum 
samples to evaluate product safety.  We develop 
protocols, perform the studies, evaluate data, write 
reports and maintain records related to the studies.  We 
do those studies under contract with the developers 
under ethical standards managed by the University 
of Nebraska as well as ethical standards of any 
collaborator’s institution.   
I have been involved in designing, performing or 
reviewing safety studies on allergenicity, toxicology 
and nutritional qualities and performance of GM 
crops and novel food ingredients for 17 years.  I 
was at the Codex Alimentarius Task Force Working 
Group meeting that was held in Vancouver Canada in 
2001 that developed the allergenicity guideline[1].  I 
have been involved in safety studies and reviewing 
procedures for GMO safety for submission to 
governments of the US, Canada, Argentina, Brazil, 
the EU, India, South Korea and Taiwan and reviewed 
hundreds of publications on allergenicity, toxicity 
and potential horizontal gene transfer.  In my career I 
have not seen any documented cases of adverse health 
problems in humans or agricultural animals caused by 
consuming approved GM crops and I believe that the 
safety assessment of GMOs is quite robust[2-3]. 
Of course I had to go through a learning process 
to gain an understanding and comfort level with the 
assessment process for GMOs because I am a born 
skeptic.  My scientific career began during the early 
years of development of agricultural biotechnology. 
This paper reviews some of the history of development 
of the safety assessment and regulation of GM crops 
in the US.  It includes the primary proven food 
safety hazards and risks and describes the process of 
evaluating safety of new GM crops prior to commercial 
UHOHDVH,WLQFOXGHVDGHVFULSWLRQRIWKHPRVWVLJQL¿FDQW
case of a GM product that was approved and then 
withdrawn from the market because of uncertainties of 
safety data, not because of harm.
1.1  Real risks of foods vs. hypothetical risks
Many of the foods we eat today were initially 
consumed hundreds to thousands of years ago.  The 
genes and exact nutritional composition of many crops 
have been changed from the earliest varieties using 
conventional breeding techniques.  However, to a great 
extent commodity crops including wheat, rice, corn and 
soybeans as well as many of the fruits and vegetables 
are quite similar to the food materials humans have 
consumed safely from these plants for centuries.  The 
experiences of using those crops have guided regulators 
in establishing a safety evaluation process that begins 
with considering whether humans have had experience 
and contact or consumption of the host plant (the gene 
recipient) and the donor organism (source of the gene 
to be transferred). 
In the mid-1970s as I was earning a bachelor’s 
degree in biology I  was an active member of 
Greenpeace, Friends of the Earth and Union of 
Concerned Scientists.  Details of techniques of 
UHFRPELQDQW'1$PHWKRGVZHUH¿UVWEHLQJGHVFULEHG
in college classrooms as we learned about potentially 
useful recombinant bacteria and plants that might come 
from the technology.  At that time most students and 
PDQ\SURIHVVRUVKDGDYHU\VXSHU¿FLDOXQGHUVWDQGLQJRI
DNA, RNA, ribosomes and protein synthesis compared 
to our knowledge in the 1990s and certainly compared 
to information available even in high school classes 
in 2014.  In the early 1970s Paul Berg, Walter Gilbert 
DQG)UHGHULFN6DQJHU DOO IXWXUH1REHO/DXUHDWHV LQ
chemistry) began discussing potential (hypothetical) 
risks that recombinant organisms might pose if certain 
viral DNA sequences from pathogens were introduced 
into bacteria using this technology.  Maxine Singer 
and others called on the community of scientists to 
develop safety standards. Much of the concern was 
on the proposed use of the simian virus 40 (SV40) 
DNA elements in recombinant bacterial plasmids that 
were being transferred in culture into monkey cells to 
understand gene function as described by Cole et al[4]. 
In response Berg and others organized the Asilomar 
Conference in 1975 at the urging of the National 
Academy of Science (US) to establish guidelines 
for ensuring safety. The process and twenty years of 
experience of safety of recombinant DNA work since 
then were reviewed by Berg and Singer[5].  Essentially 
all recombinant DNA work was halted in the US for 
one year while the guidelines were developed.  They 
detailed considerations based on perceived risks and 
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called for the establishment of institutional biosafety 
committees to review each new rDNA experiment 
in any institution or company that was performing 
genetic engineering research.  The primary focus was 
the potential risk or safety of the new DNA elements 
based on mode of action and risk of the DNA donor 
organism.  The guidelines have helped ensure that 
really hazardous organisms were not created using the 
technology.  Relatively safe cloning experiments can 
be performed in a typical clean laboratory environment 
with few restrictions (Biosafety level 1 or 2). There 
are few places with extremely tight controls (Biosafety 
level 3 or 4) where recombinant experiments can be 
performed on highly lethal and infectious agents (KWWS
HQZLNLSHGLDRUJZLNL%LRVDIHW\BOHYHO).  
The safety issues related to foods derived from GM 
plants are of course different.  Genetically modified 
plants are not infectious, potential risks of food 
safety for GMO are quite low compared to risks from 
microbes and risks are not different from those posed 
E\QRQ*02SODQWV7KHUHDUHRIFRXUVHVSHFL¿FULVNV
from foods that must be evaluated such as the potential 
transfer of an allergen or a toxin from another organism 
into a food crop. Many hypothetical risks are the focus 
RIGLVFXVVLRQWRGD\UDWKHUWKDQWKH¿QLWHDQGGH¿QDEOH
risks that should be evaluated based on our extensive 
knowledge of science and safety.  The evaluation of a 
new product that has added one or a few new gene(s), 
new protein(s), or new metabolites to a crop that has 
10 000 to 20 000 endogenous genes and has already 
been safely consumed should focus on the safety of the 
gene source, protein characteristics and metabolites if 
the protein is an enzyme. The risks would be presented 
by the other 10 000 plus genes and proteins would be 
the same risks that already occur from that crop.  In 
addition, the types of risks the new gene and protein 
could present are definable based on our experiences 
with other foods. Most current non-GM food crops 
KDYHVSHFL¿FDOOHUJHQLFSURWHLQVDIHZPD\KDYHWR[LQV
(solanine) or anti-nutrients (trypsin inhibitors). So the 
focus on the new proteins should be on evaluating 
potential allergenicity, toxicity and any anti-nutritional 
properties.  
There is now a history of nearly 20 years of 
production and consumption of a few commonly 
grown GM crops, for example insect protected 
corn containing a specific protein from Bacillus 
WKXULQJLHQVLVRU%WFRUQKHUELFLGH WROHUDQWVR\EHDQV
with a gene from a soil bacterium and virus resistant 
papaya, without evidence of harm.  Crops improved 
through biotechnology have shown benefits due of 
reduced pesticide applications or in some cases reduced 
plant pathogen impacts.  A number of GM crops have 
improved agricultural practices in ways that minimize 
soil erosion, energy or water consumption. 
Some might argue that the strong fears voiced 
against GMOs stimulate healthy debates about proper 
regulatory studies that have helped ensure a robust 
assessment process. Others suggest that many of the 
new regulatory demands developers face today are 
excessive and delay scientific progress in medicine, 
industrial development and agriculture. The truth 
probably lies between the extremes, but based on 
conversations with GM developers, commodity 
companies and food companies as well as review of 
regulatory guidelines of the EU and other countries 
it is clear that the global process of GM evaluation 
and approvals are slowing development and leading 
to global trade barriers over the past 10 (2004 to 
2014) years.  Because of the international nature 
of trade, agricultural companies have to wait many 
years before new products can be released in order 
to obtain approvals in the major world markets.  It 
seems that regulators in all countries are becoming 
more precautionary as they are afraid of being 
blamed for approval of a GM crop that is not proven 
to be absolutely safe under all possible uses.  The 
precautionary principle is counter to the policy of the 
Food and Drug Administration (FDA) of the US as 
outlined in 1994, which recognized that all foods pose 
some risks that can be evaluated and managed and that 
the standard of safety is that foods from GM crops 
must be as safe as conventional crops of similar types.  
A searching of scientific literature today identifies 
many new study questions and designs that are being 
performed on potential GM crops using a variety of 
search terms (transgenic, GM,  genetically engineered, 
toxicology, reproductive, cancer) that should only 
be performed if there is as testable hypothesis based 
on information about the crop or the gene and 
gene products. Few (if any) dietary proteins alter 
UHSURGXFWLYH¿WQHVVFDXVHFDQFHUDFWDVDGMXYDQWVRU
increase the prevalence of a broad range of autoimmune 
diseases.  
Today regulators and politicians are being pressured 
by activists like Eric-Gilles Seralini, Terje Traavik, 
Vandana Shiva, Mae-Wan Ho and Jeffrey Smith as 
well as celebrities like Oprah Winfrey, Dr. Oz and Cui 
Yongyuan or by consumers who listen to these activists 
make unsubstantiated claims of health risks of GMOs 
on websites in books, in the news media and television. 
For example, Jeffrey Smith’s website, the deceptive 
5LFKDUG(*RRGPDQ%LRVDIHW\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“Institute for Responsible Technology (KWWSZZZ
UHVSRQVLEOHWHFKQRORJ\RUJ) claims that very diverse 
human diseases including autism, celiac disease, food 
allergies and cancers are dramatically increasing due 
to increased consumption of foods produced from GM 
crops.  He takes small observations from a few poorly 
controlled animal studies that have not been validated 
to predict human disease and implies that humans will 
experience many complicated diseases from eating 
foods derived from GMOs. Mr. Smith offers a training 
program for “anti-GMO speakers” for a fee of $150 
USD.  Mr. Smith does not post credible peer-reviewed 
scientific studies to support his claims and generally 
cites correlations of increased GMO production and 
increases in these diseases that have highly diverse 
and uncertain causes. In fact the correlations usually 
do not match the introduction of most of the GMOs 
in the food chain. Yet many highly educated people 
take statements by Smith and other activists to be 
factual and they refuse to look more deeply for the 
many public and published studies that are available to 
demonstrate the approved GMOs have been evaluated 
for safety by scientifically sound studies. There are 
no studies that link consumption of insect-protected 
corn to celiac disease or food allergies, nor autism 
nor cancers.  If coincidental changes in our lives and 
HQYLURQPHQWGHPRQVWUDWHGFDXVDOLW\ZHVKRXOGVWRS
air-travel, shut off the internet, discard cell phones 
DQG WHOHYLVLRQ EDQSURFHVVHG IRRGV YDFFLQHV DQG
prescription medications.  We would need to live our 
lives as they were in 1914 when the world population 
was less than two billion, life was very different and 
the average life-expectancy less.     
In considering risks from foods, it is highly doubtful 
that genetic diversity of our foods represents a food 
safety risk.  We are omnivores and subsist on highly 
diverse diets.  We consume foods that are markedly 
different in 2014 compared to those consumed in 
1914 and certainly compared to 1514 before tomatoes, 
potatoes and peppers were transferred from South 
America to Europe, India and China.  If there are 
VLJQL¿FDQWO\GLIIHUHQWULVNVDVVRFLDWHGZLWKHDWLQJSODQWV
that have only minor genetic differences compared to 
the varieties we eat every day, then maybe we need 
very complicated testing methods.  However, humans 
have been pretty good at evaluating food safety over 
thousands of years without highly complex scientific 
studies.  One could argue the extended life-expectancy, 
relatively low infant mortality rates and general health 
status of humans in the US and China in 2014 provides 
pretty convincing evidence that the current GMOs 
are not likely to be harmful. It is important to focus 
on realistic risks of foods and the development of 
processes that help ensure that foods produced from 
GM crops are as safe as foods produced from similar 
non-GM crops.
1.2  Early development of the safety evaluation of 
GMOs
In the mid-1980s I had not considered the safety 
assessment process that might be performed on GM 
crops to evaluate food safety.  I knew little about the 
process of using agrobacterium mediated transformation 
system to insert functional segments of DNA into 
plants[6]. As I learned more about biotechnology during 
training as a PhD student at the Ohio State University, 
cloning a cDNA of bovine lactoferrin for sequencing 
and expression I had to learn and comply with 
evaluations by institutional review committees at the 
university.  I had to answer questions about the source 
of the gene, the encoded protein, the plasmid vectors 
and the host cells and organism that was to receive 
the cloned DNA.  The training was reinforced during 
my work developing cDNA clones for rodent and 
human cytokines as I studied immunology at Cornell 
University and later at the University of Michigan.  By 
the time I joined Monsanto as a regulatory scientist 
working on the safety assessment of GM plants in 
1997, I stopped believing the statements by Greenpeace 
and others about many hypothetical risks of GM crops 
and statements that there were no safety evaluations 
and resigned my memberships in those organizations. 
Within two months of joining Monsanto I was thrust 
into the role of developing an animal model to evaluate 
the potential impact of a GM event to evaluate potential 
impacts on allergenicity.  The tests were novel and 
unprecedented as no one had demonstrated that a rodent 
model could predict potential sensitization in humans. 
However the government of India demanded an animal 
model test for allergenicity.  The approval process took 
nearly 7 years after the US had approved the same 
crop.  India dropped the requirement to use animal 
models to evaluate potential risks of food allergy after 
bringing their guidelines into alignment of the Codex 
Alimentarius Commission (2003) guideline[1] in 2008. 
My work at Monsanto involved becoming familiar with 
the regulatory process in the US and other countries 
and learning the science of risk evaluation for potential 
allergenicity, toxicity and nutritional equivalence. I 
continued being involved in the regulatory evaluation 
process when I was hired at the University of Nebraska 
in 2004 and have become even more broadly involved 
through 2014. But I am still learning about the process 
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that led to the current assessment.
A review of publically available information shows 
that academic, industrial and government scientists 
have collaborated in many consultations to develop 
a useful and predictive safety assessment process for 
GM crops.  The US government outlined a coordinated 
regulatory framework in 1986 that includes the Food 
and Drug Administration (FDA) the Environmental 
Protection Agency (EPA) and the US Department of 
$JULFXOWXUHWRHYDOXDWHDQGUHJXODWH*0FURSV2I¿FH
RI6FLHQFHDQG7HFKQRORJ\3ROLF\KWWSZZZ
DSKLVXVGDJRYEUVIHGUHJLVWHUFRRUGLQDWHGBIUDPHZRUN
pdf).  That was eight years before the first GM crop 
approval.  A group of academic and industrial scientists 
held meetings as the International Food Biotechnology 
Council (IFBC) in collaboration with the International 
/LIH 6FLHQFHV ,QVWLWXWH ,/6, DQG GHYHORSHG D
risk assessment guideline that was published as a 
supplement to volume 12 of Regulatory Toxicology and 
Pharmacology (1990)[7] 7KH,)%&,/6,YROXPHZDV
prepared by 28 highly experienced scientists and legal 
experts.  The volume presented methods of genetic 
modification, variable crop composition of traditional 
foods, safety evaluation of food ingredients derived 
from microorganisms, safety evaluation of single 
chemical entities, safety evaluation of whole foods 
and complex mixtures and legal and regulatory issues. 
The draft reports were reviewed by 150 experts in 
industry, government and academia from 13 countries 
prior to publication. The major issues were presented 
and discussed by 120 experts in an open symposium. 
7KH,)%&,/6,GRFXPHQWSUHVHQWHGDQXPEHURINH\
evaluation steps and decisions for whether further 
evaluations were necessary and also discussed the legal 
food safety regulatory framework in the US.  They 
supported the decision by the US government that 
foods derived from GM products could be efficiently 
regulated within the existing regulatory framework 
as they found that generating the new varieties (e.g., 
transformation through biolistics or Agrobacterium 
constructs) were not different in terms of potential 
impacts on safety compared to traditional breeding 
methods.  The panel concluded the focus should be 
on questions related to characterizing and evaluating 
the safety of the introduced DNA, proteins and any 
metabolic products of any new enzyme in the GMO.
1.3  US regulatory process for GMO evaluations
In 1992 the FDA issued a policy statement on the 
safety and evaluation process for foods derived from 
new plant varieties including those derived from 
recombinant DNA techniques under the Federal Food, 
Drug and Cosmetic act (FDA Federal Register vol. 
57, No. 104, docket No. 92N-0139).  The evaluation 
process was followed for the safety assessment of the 
first GM crop approvals in 1994-1995 and although 
more complex now, are consistent with the process 
IROORZHGLQ8QGHUWKHXQL¿HGUHJXODWRU\V\VWHP
the US Department of Agriculture (USDA) Agricultural 
and Plant Health Inspection Service (APHIS) is 
responsible for oversight of regulated field trials of 
unapproved GM events, control through a permit 
system of GM organisms, plant pests and veterinary 
products.  A different section of USDA, the Food 
Safety and Inspection Service (FSIS) is responsible 
for regulating the safety of meat and some poultry 
products.  The FDA has authority of other food safety 
issues including evaluating the safety of GM crops 
and all milk and dairy ingredients. The Environmental 
Protection Agency (EPA) is the lead agency involved in 
evaluating GM plant incorporate pesticidal (PIP) genes 
(e.g. plants containing genes encoding crystal proteins 
from Bacillus thuringiensis RU%W SODQWV SODQWV
including genes for viral resistance such as the Plum 
Pox Virus resistant plum tree) as well as regulating 
chemical herbicides and chemical insecticides. The 
EPA and FDA follow the same food safety guidelines 
and the normal process for a PIP includes consultations 
with the FDA and a full dossier submission to the EPA. 
Although the FDA consultation and data submission 
is in theory “voluntary”, failure to consult with FDA 
and provide data to complete evaluation of potential 
allergenicity, toxicity and nutritional effects of a GM 
crop is likely to lead to mandatory recall and legal 
action if there is any suspicion of harm. Requirements 
by EPA and USDA are clearly mandatory.  Both the 
EPA and the FDA expect similar evaluation processes 
and tests for food safety before a product goes to 
market.
1.4  FDA policy on food safety of GMOs: as safe 
as similar varieties of non-GMOs
The FDA and regulatory agencies from Australia, 
Brazil, Canada, Japan, the Netherlands and the United 
Kingdom governments were significant contributors 
to the Codex 2003 guidelines[1] that were established 
as part of the Codex system that is agreed to by the 
US and China.  The process includes evaluation of the 
same types of risks presented by non-GMO sourced 
foods that are known to cause adverse health effects: 
food allergy, food toxicity and adverse nutritional 
effects including potential increases in anti-nutrients or 
inclusion of potential celiac eliciting proteins (glutens 
from wheat and near-wheat relatives). Developers 
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are expected to present documented information 
evaluating the history of safe human use (HOSU) or 
exposure of the gene source and protein or gene, as 
well as information showing adverse effects.  The 
information must include characterization of the gene 
products (protein or RNA) and any metabolites of 
any introduced enzyme, dose of consumption of the 
protein or metabolites that will be expressed in the 
new GM plant food material based on consumption 
patterns of foods made from the host organism.  If 
there is historical evidence showing potential risk from 
consumption of the gene donor, additional testing may 
be required.  
The FDA recognized that a few endogenous 
ingredients of all foods pose some risks for consumers. 
Some risks are normally mitigated by food storage, 
preparation (cooking) or limiting consumption. For 
instance lectins, protease inhibitors and amylase 
inhibitors of legumes (beans) are inactivated by 
cooking prior to consumption.  Cassava is soaked and 
pressed to remove hydrocyanic acid to prevent cyanide 
poisoning before manioc is made and consumed. 
Potato varieties are selected in breeding to ensure they 
have low concentrations of the glycoalkyloid solanine 
as it is a mild toxicant. Young, green potatoes are not 
consumed as the content of solanine is high at that 
stage. Humans have adapted the foods and processing 
to ensure safety.  Those hazards affect essentially 
all consumers if not handled appropriately. Other 
hazards that affect everyone are from contamination by 
bacteria, fungi or chemicals.  
I t  i s  impor tant  to  recognize  tha t  the  most 
common and severe risks of food ingestion are from 
contamination of food with exogenous materials. 
Contamination can occur on the farm, or during 
storage in restaurants or homes. Bacteria, viruses, 
fungi, parasites and chemicals including mycotoxins, 
heavy metals and pesticides are relatively common 
food contaminants.  The most significant acute risks 
are presented by bacteria including Escherichia coli 
2 DQG RWKHU WR[LQ SURGXFLQJ VWUDLQVListeria 
monocytogenes, Salmonella sp., Campylobacter sp, 
and Clostridium perfringens.  The Center for Disease 
Control (CDC) and USDA FSIS estimate that there 
will be approximately 3 000 deaths in 2014 in the 
US population of 310 million, and approximately 
128 000 hospitalizations (ZZZIRRGVDIHW\JRY
SRLVRQLQJFDXVHV). Some parasites are also commonly 
spread through food. Toxoplasmosis is caused by 
Toxoplasma gondii, the most common food borne 
parasite in the US causing hospitalization and some 
deaths.   Some viruses are commonly spread through 
foods. Norovirus is the most common cause of acute 
gastroenteritis in the US.  It is spread through contact 
with many foods due to unsanitary food handling in a 
given outbreak, but rarely causes fatalities.  Hepatitis 
A can lead to death in susceptible individuals who go 
untreated.  Mold contamination is rarely documented 
DVDFDXVHRIVLJQL¿FDQWIRRGERUQHLOOQHVVLQKXPDQV
with the exception occasional outbreaks of mycotoxin 
poisoning caused by moldy grains[8].  However, 
mycotoxins more commonly cause severe outbreaks 
in poultry and other agriculturally important species 
as they are often fed grain at high concentrations[8]. 
Mycotoxins are small to moderate molecular weight 
organic compounds that are typically polycyclic and are 
not easily detoxified by the liver of some individuals 
or species. A few of the substances that cause toxic 
reactions are proteins, such as botulinum which is 
produced by the bacteria Clostridium botulinum along 
with some other toxins while ricin from castor beans 
is one of the rare plant protein toxins known to affect 
mammals[9].  Interestingly GM plants expressing plant 
incorporated protectants such as Cry1A in corn can 
reduce fumonisin (a mycotoxin) levels, thus reducing 
the potential for toxicity in chickens, pigs and cattle. 
)XWXUH*0SURGXFWVDUHOLNHO\WRLQFOXGHVSHFL¿FDQWL
fungal and anti-microbial proteins that will further 
enhance food safety.  
While toxins and anti-nutrients often affect nearly 
every consumer, a few hazards in foods only affect 
a small percentage of the population.  Specific food 
allergens affect less than 1% of the population, but can 
cause severe reactions or death in a very small percent 
of the population.  Glutens (gliadins and glutenins) of 
wheat and closely related grains cause celiac disease 
(CD), a chronic autoimmune disease in less than 1.5% 
of the population.  Celiac disease affects a genetically 
restricted subset of the population that includes over 
25% of the total population and there are many other 
factors that are not completely understood.  A major 
focus of the food safety assessment then is to evaluate 
and ensure that the transfer of a gene into a GM plant 
does not transfer an allergen or a CD eliciting gluten 
from the allergenic or CD eliciting source into another 
source.
1.5 Recognized risks of food allergy including 
celiac disease in non-GM crops
The most  common endogenous r isks  of  food 
consumption are IgE mediated food allergies[10] and 
cell-mediated celiac disease[11-13].  Food allergy to all 
sources may affect 2% to 6% of the population in the 
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US, with varied degrees of severity.  Individuals are 
usually sensitive to between one and five allergenic 
foods.  Allergens pose a significant risk to those who 
DUHDOUHDG\DOOHUJLFWRWKHVSHFL¿FSURWHLQVZKLOHWKH\
do not pose a risk for non-allergic consumers.  Because 
food allergy is highly variable between subjects in 
terms of severity of disease and the complexity of food 
composition, the sources of allergy for an individual 
are not always obvious[14-15]. The methods used for 
diagnosing food allergy are not standardized in many 
medical facilities and few doctors are well trained to 
accurately diagnose food allergy[16-17].  Food allergies 
are specific because the patient has been sensitized 
and produces IgE antibodies that bind specifically to 
one or more proteins in the food.  In IgE mediated 
food allergy, reactions occur because the individual 
has developed specific IgE antibodies to at least two 
epitopes (IgE binding sites) on a relatively abundant 
protein in the food.  Their IgE antibodies are bound to 
)Fİ5UHFHSWRUVRQWKHVXUIDFHRIPXFRVDOPDVWFHOOV
and blood basophils. Upon subsequent ingestion of the 
food containing the allergenic protein, the protein or 
fragments of the protein are absorbed and bind IgE on 
the mast cells or basophils, stimulating signals within 
WKHFHOO,IDVXI¿FLHQWQXPEHURIDOOHUJHQ,J(ELQGLQJ
events occur within a few minutes it triggers the release 
of histamine and leukotrienes from the mast cells and 
basophils, inducing vascular leakage and symptoms 
due to angioedema and nerve stimulation.  Some 
individuals experience relatively mild oral itching and 
mild swelling (angioedema) in the mouth and throat, 
others get hives or urticaria.  Some experience asthma 
with wheeze and shortness of breath. Others may vomit 
or have diarrhea. A few will experience hypotension 
(drop in blood pressure). Anaphylaxis is a severe, life-
threatening systemic reaction that includes hypotension 
DQGEUHDWKLQJGLI¿FXOW\WKDWXVXDOO\UHTXLUHVLPPHGLDWH
medical attention including injection of epinephrine, 
other medications and oxygen.  Perhaps 150 to 200 
highly allergic individuals in the US die each year due 
from anaphylaxis triggered by food allergy[18].  Most 
who died because they did not receive immediate 
medical treatment including an injection of epinephrine. 
Peanuts, a few tree nut species, milk and eggs are the 
most common causes of fatal anaphylaxis from food[19]. 
Although exposure to the allergen triggers an acute 
reaction in the allergic individual, once sensitized, the 
individual may remain allergic throughout their life. 
However, young children often become tolerant to their 
allergenic food (milk, soybeans or egg) five or more 
years after initial reactions through a process leading to 
immune tolerance. 
Estimates of the prevalence of food allergy are 
approximations.  The best estimates available for the 
US, Europe and Japan indicate that food allergy affects 
from between 1% and 2%, up to 10% of the general 
population in those countries[20-21].  The frequency of 
cases of severe, life-threatening reactions is not well 
established, but clearly some allergenic foods such as 
peanuts, some tree nuts, cow’s milk and eggs account 
for more severe reactions than fruits and vegetables. In 
most countries including the US there has not been a 
standard reporting system for food allergy anaphylaxis. 
Epidemiologists at the US Centers for Disease Control 
reviewed hospital coding within the US system for 
a period of 1997-2007 using various resources and 
estimated that there are approximately 317 000 food 
allergy related hospital visits per year in the US (years 
2003-2006), with more than 9 000 admissions due to 
severe reactions[22].  Anaphylaxis was usually attributed 
to peanuts, crustacean shellfish (shrimp), tree nuts, 
PLONHJJVDQG¿VK
Celiac disease is a genetically restricted autoimmune 
disease initiated by sensitization to specific wheat, 
barley and rye glutens (gliadins and glutenins) by 
activation of T helper 1 type CD4+  T cells[23].  The 
disease is chronic and lead to flattening of the villi 
in the upper small intestine, wasting disease and 
VRPHWLPHVWRVSHFL¿FFDQFHUVDQGRWKHUDXWRLQPPXQH
diseases. The genetic restriction is due to unusual 
protein sequences that are presented most effectively 
by those with Major Histocompatability Complex loci 
+/$'4RU+/$'4[24].  However, while more 
WKDQRIWKH86SRSXODWLRQKDVHLWKHU+/$'4
or DQ-8, only an estimated 1% of US consumers are 
clearly diagnosed with CD, which is similar to the rate 
in Europe[25]. The rate of CD in China is not known, but 
one recent study suggests that it is more common than 
once believed[26]. There are uncertainties in prevalence 
due to the complexity of accurately diagnosing affected 
individuals as endoscopy with multiple biopsies are 
taken as the gold standard following consumption 
of  glutens,  but  endomesial-specif ic  or  t issue 
WUDQVJOXWDPLQDVHVSHFL¿FDQWLERG\WHVWVLQFRQMXQFWLRQ
ZLWK+/$W\SLQJRUDVVRFLDWLRQVZLWKGLDJQRVHGQHDU
relatives are often used as sufficient evidence for 
diagnosis[27] 6SHFL¿FSHSWLGHVRIJOXWHQVDQGJOLDGLQV
have been identified as stimulating Th1 CD4+ T cell 
clones from MHC-restricted CD patients[28-30]. The 
only way CD patients manage their disease is through 
avoiding consumption of foods containing proteins 
from wheat, barley, rye and for some, oats[31].  There is 
5LFKDUG(*RRGPDQ%LRVDIHW\HYDOXDWLRQDQGUHJXODWLRQRI*HQHWLFDOO\0RGL¿HG*0 93
also a growing number of consumers who believe they 
KDYHQRQFHOLDFJOXWHQVHQVLWLYLW\KRZHYHUWKHVSHFL¿F
disease pattern is not uniform, the mechanism of 
reactions are not known and there is some disagreement 
between Gastroenterologists as to the authenticity of 
the disease[32]. 
)RRGDOOHUJHQVDUHVSHFL¿FSURWHLQVQRWZKROH
foods
Generally people describe food allergy as being a 
reaction to a whole food (e.g. milk, eggs or peanuts). 
But research over the past two decades has identified 
VSHFL¿FSURWHLQVLQWKHIRRGVDVWKHFDXVHVRIDOOHUJ\
The International Union of Immunological Societies 
(IUIS) Allergen Nomenclature Subcommittee (www.
allergen.org) lists 12 protein families as commonly 
allergenic.  The most prominently named peanut 
proteins reported as the dominant allergens are the 
small molecular weight prolamins (14 to 18 kDa) 
including the abundant 2S albumins (Ara h 2 and 
Ara h 6) and higher molecular weight cupins (50 to 
75 kDa) major seed storage proteins, Ara h 1 and Ara 
h 3. The cupins each account for more than 15% of 
the total protein content of the seeds.  Subjects with 
substantial IgE concentrations to any of these four 
proteins are most at risk for severe reactions following 
ingestion of peanut[33-34].  The Ara h 2 and 6 proteins 
are highly cross-linked small molecular weight proteins 
with four intra-chain disulfide bonds making them 
relatively resistant to digestion by the stomach protease 
pepsin[35-36] $IHZRWKHUSURWHLQVKDYHEHHQLGHQWL¿HG
as allergens in peanuts but represent low abundance 
DQGRUORZVWDELOLW\SURWHLQVZKLFKDUHFRQVLGHUHGWREH
minor allergens.   Most people with clear IgE mediated 
allergy to peanut have IgE to the major allergenic 
proteins, it is not clear that IgE to the minor allergens 
FDXVHVLJQL¿FDQWFOLQLFDOUHDFWLYLW\ $IHZSURWHLQVLQ
some foods are nearly identical to homologous proteins 
in other foods or in pollen and are considered pan-
allergens since the IgE of one subject may bind the 
homologous proteins from a wide variety of species. 
The pan-allergens do not cause serious reactions in 
most allergic subjects.  Pan-allergens in peanuts include 
profilin (Ara h 5), pathogenesis related protein-10 
family members (Ara h 8.0101 and Ara h 8.0201) and a 
OLSLGWUDQVIHUSURWHLQ/73$UDK7KHVHTXHQFHVRI
two defensin proteins Ara h 12 and Ara h 13 recognized 
by the IUIS nomenclature committee has not yet been 
published and the frequency and severity of induced 
allergic reactions are unknown.  Individuals allergic 
to tree nuts including almonds, hazelnuts, pecans and 
walnuts usually have IgE antibodies that recognize 
similar 2S albumins and cupin seed storage proteins. 
In some cases there seems to be cross-reactivity 
among the tree nut proteins and even to peanut, but 
it is difficult to separate IgE cross-reactivity from de 
novo sensitization, where a subject is co-sensitized and 
co-reactive. Certainly though pecans and walnuts are 
very closely related and their allergenic proteins nearly 
identical. 
A number of individual IgE-binding allergenic 
proteins from foods, inhalation sources (pollen, house 
dust mites and mold spores) and dermal (latex) or 
injection (venom, saliva of biting insects) sources have 
been characterized and studied in the past 25 years. 
The sequences of the proteins with published proof 
of IgE binding using sera from appropriately allergic 
subjects have been included in the AllergenOnline.
org database managed by the Food Allergy Research 
and Resource Program at the University of Nebraska-
/LQFROQ www.AllergenOnline.org) to provide a 
bioinformatics tool for the GM safety assessment 
process.  A number of the proteins included in the 
Allergen Online database have also been demonstrated 
to cause biological reactivity by skin prick tests of 
allergic subjects, basophil histamine release or basophil 
DFWLYDWLRQDQGWKRVHSURWHLQVDUHPRUHUHOLDEO\GH¿QHG
as allergens. The references used to categorize each 
allergenic protein group are listed in the database (www.
AllergenOnline.org) along with an explanation of the 
process of classification. The database also provides 
sequence comparison algorithms to evaluate potential 
new GM or novel food proteins for potential risks of 
cross-reactivity. 
It is not clear why people become allergic to certain 
proteins and foods rather than becoming tolerant to 
these generally innocuous proteins although there 
are genetic risk factors for IgE mediated allergy.  It 
is clear that the prevalence of food allergy is rising 
in industrialized countries and it cannot be explained 
by changes in the genetics of consumers[37].  There 
are a number of proposed mechanisms including the 
“hygiene” hypothesis (lack of certain bacterial types 
from the environment or within the gastrointestinal 
tract) for sensitization (induction of specific IgE) 
and tolerance (suppression of IgE and allergy), but 
no single markers or hypothesis fits everyone[37]. 
Very likely multiple factors interact at the time of 
introduction of foods in the developing child, food 
processing methods, reduced vitamin D levels due to 
sedentary indoor lifestyles and reduced exposure to 
certain microorganisms or reduced parasite burden 
that together are contributing to increases in allergic 
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disease. 
Celiac disease is elicited by a limited number of 
glutenins and gliadins from wheat, barley, rye and 
possibly oats, all members of the Pooideae subfamily 
of grasses. In order to provide a possible risk 
assessment tool for food safety assessment, we have 
gathered 1 016 peptides and 58 proteins f that have 
been found to stimulate CD restricted T cells into a 
&'VSHFL¿FGDWDEDVHIRUXVHLQULVNDVVHVVPHQWwww.
DOOHUJHQRQOLQHRUJFHOLDFKRPHVKWPO). We have also 
developed bioinformatics tools that help evaluate novel 
food proteins for identity matches to be able to flag 
potentially important proteins as possible risky proteins 
for those with CD to consume.
2  Assessment of GM crop safety 
in the US 
2.1  History of safe use (HOSU)
The scope of the HOSU evaluation of the gene source, 
WKHJHQHUHFLSLHQWDQGWKHVSHFL¿FSURGXFWVRIWKHJHQH
includes determining whether there is documentation of 
direct contact with the protein or indirect contact with 
metabolites if the protein is an enzyme. Descriptions 
of appropriate allergenicity and toxicity assessments 
have been published by experienced scientists who 
have expertise in those areas[9,38].  In cases where the 
gene source is a common cause of allergy or toxicity, 
additional tests are likely to be required compared 
to sources without any history of allergy or toxicity. 
For example, peanuts and certain tree nuts (walnut, 
pecan, almond and hazelnut) are considered common 
causes of allergy.  If a gene is transferred from one 
of the commonly allergenic sources, specific serum 
IgE testing is likely to be required similar to the study 
performed by Nordlee et al., for the Brazil nut 2S 
albumin[39]. If the gene source is castor bean (Ricinus 
communis), the Closteridium botunlinum bacterium or 
a wasp (Vespula germanica), regulators are likely to 
ask for additional specific toxicity tests to verify that 
WKHSURWHLQLVQRWDWR[LQ6SHFL¿FWHVWLQJUHTXLUHPHQWV
will be dictated by the nature of the risk. If the source 
has neurotoxicity, then neurotoxicity tests are likely 
to be called for.  The identifiable risks of the source 
would normally be discovered by searching published 
peer reviewed literature, although sometimes sources 
including searching Google may be useful.  If there is 
a clear history of consumption of the source material, 
and the protein in question is proven to be expressed 
in the material that is consumed (e.g. the nut, fruit 
or herbaceous material), the lack of allergenicity or 
toxicity would aid in determining the protein is unlikely 
to present a risk. However, in many cases there will 
not be a history of safe consumption, which does not 
automatically mean additional tests are required, only 
that there may be slightly less certainty of safety.  
Often there are clear, restricted risks associated with 
a given gene source.  Apples contains two proteins 
that might be considered significant allergens, a non-
VSHFLILF/73WKDW LVNQRZQWRFDXVHVHYHUHDOOHUJ\LQ
a very small number of consumers and a less potent, 
common cross-reactive protein Mal d 1. The Mal 
d 1 protein is a sequence similar homologue of an 
airway allergen Bet v 1 that is common in pollen of 
birch and related tree species.  Other proteins from 
apple are expected to represent low or no risks of food 
allergy.  Peanuts contain four potent allergens and a 
few additional minor allergens. Food labeling laws are 
written to differentiate risks of food allergy based on 
the prevalence and severity of allergy to the sources. 
In the US, Europe and Japan, peanuts are considered 
common and important sources of food allergy and any 
processed food that contains an ingredient from peanut 
must be labeled as to source.  Apples are not considered 
to be common, potent sources of food allergy.  The 
safety of proteins derived from a peanut gene would be 
more thoroughly evaluated than a protein from apples 
for potential risks of allergy.  
The source of the insecticidal crystal proteins 
Cry1A, Cry2A and Cry3A is the bacterium Bacillus 
thuringiensis.  Spores of this species have been used as 
microbial pesticides for 70 years without demonstration 
that they cause allergies or toxicity in mammals. The 
historical safe use of the organic pesticides provides 
assurance of HOSU for some Bt toxins, although that 
is true only for proteins that are demonstrated to be 
expressed by the bacteria used as microbial pesticides 
and not from all varieties of the species.  
The developer is expected to provide documentation 
of the history of safe use of the gene source organism 
and if possible of the gene products.  The description 
should also include evidence that the protein or 
other gene products are expressed in the materials 
encountered in food as well as a description of 
preparation of the food. 
&KDUDFWHUL]LQJ WKHQHZSURWHLQDQGSURGXFW
attributes
The developer must describe the DNA or RNA 
sequence transferred in making the GMO.  The source 
of other genetic elements (promoter and terminator) in 
the construct must be included.  The method of transfer 
must be defined.  Confirmation of copy number, 
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gene integrity and stability of the DNA through 
reproductive cycles of the organism must be verified. 
Any gene product should be quantitatively measured 
under conditions of normal use of the plant.  In some 
cases mRNA size and accumulation in various plant 
tissues are also necessary to ensure the transcript is as 
expected.  In most cases the gene encodes a protein. If 
the protein is an enzyme, any expected and measured 
metabolites must be described. The function of the gene 
and products must be disclosed.  The sequence of the 
DNA and the protein are disclosed and data comparing 
the protein amino acid sequence to known toxins and 
allergens must be evaluated. 
2.3 Potential allergenicity
Due to the importance of food allergies, the FDA has 
focused on preventing the transfer of allergens into a 
new food source as a primary concern for GM crops. 
A major risk for consumers with allergy to peanuts 
would be the transfer of a gene encoding a major 
peanut allergen into rice or corn.  That possibility was 
demonstrated by the experience of Pioneer Hi-Bred 
when they transferred a gene encoding the 2S albumin 
from Brazil nut into soybean to improve feed quality 
for animals.  Soybeans have a high concentration of 
protein, but are deficient in sulfur containing amino 
acids. The 2S albumin of Brazil nut is a small protein 
with a high concentration of methionine and cysteine 
amino acids.  Pioneer Hi-Bred was preparing a dossier 
for submission for regulatory review for this potential 
product when they consulted with Dr. Steve Taylor at 
the University of Nebraska who suggested that since 
Brazil nut is known to cause food allergy in some 
consumers, the protein expressed by the transferred 
gene should be evaluated for potential allergenicity. In 
1995 no one knew what the allergenic proteins were 
in Brazil nuts, but during studies described by Nordlee 
et al.[39], it became apparent that the 2S albumin is an 
important allergen.  The results were published and 
Pioneer Hi-Bred stopped development of that potential 
product without submitting it to regulators.  The 
experience helped validate the evaluation process that 
had been outlined in the FDA Federal Register in 1992. 
The experience also helped crystalize the evaluation 
process outlined by Metcalfe et al.[40], for evaluating 
potential allergenicity of GM proteins and eventually 
the Codex Alimentarius Commission guideline first 
published in 2003[1].  
Food allergy is usually restricted to reactions 
mediated by antigen specific IgE antibodies and the 
mechanisms described can be found in any immunology 
text book. Most dietary proteins stimulate the immune 
system to become tolerant to contact with the protein. 
However, for those prone to allergies, their T helper 
cells and B cells may become educated to develop IgE 
immunoglobulin production because of the mixture of 
cytokines and cell surface signals provided by T-helper 
type 2 cells.  The B cells differentiate into plasma cells 
or B memory cells expressing high levels of protein-
VSHFLILF ,J( WKDWEHFRPHVERXQG WR WKH)Fİ5,KLJK
DI¿QLW\UHFHSWRUVRQPXFRVDORUGHUPDOPDVWFHOOVDQG
blood basophils.  When the antigen is absorbed again in 
subsequent meals, it cross-links IgE antibodies on the 
receptors if at least two epitopes are bound and initiates 
DVLJQDOFDVFDGH ,IDVXI¿FLHQWQXPEHURIFURVVOLQNV
occur within a few minutes the mast-cells or basophils 
releases histamine, leukotrienes and proteases that elicit 
vascular leakage and inflammation.  Symptoms may 
include angioedema, urticarial, asthma, emesis (vomit), 
hypotension (drop in blood-pressure) and in rare cases 
death due to systemic anaphylaxis.  Since the IgE 
antibodies are specific in peptide epitope recognition, 
WKHV\PSWRPVDUHUHSURGXFLEOHVDPHDQWLJHQVLPLODU
reactions.  Generally allergic sensitivity is assumed to 
be life-long. Many dietary proteins also induce IgG and 
IgA antibodies, but those are not risk factors for acute 
food allergy.  Production of these immunoglobulins by 
B cells also requires T cell help, but the responses and 
signals differ from those leading to IgE responses.  The 
focus of the allergenicity evaluation is therefore on 
measuring IgE responses.  
There are also T-cell mediated reactions to some 
dietary proteins, the major one being gluten-sensitive 
enteropathy or CD as discussed previously.  Evaluating 
GM proteins for potentially eliciting CD is relatively 
straight-forward and will be discussed later.  There 
are rare cases of T cell mediated food protein induced 
enterocolitis syndrome (FPIES), which is a severe 
reaction primarily to proteins in cow’s milk or soybean 
but occasionally to proteins in rice or oats and a few 
other foods[41]. Individuals usually become tolerant to 
WKHUHVSRQVLEOHIRRGZLWKLQWKUHHWR¿YH\HDUVDQGQR
VSHFL¿FSURWHLQVKDYHEHHQLGHQWL¿HGDVWKHFDXVDWLYH
agents.  Therefore it is not possible to evaluate proteins 
as a possible cause of FPIES at this time.
There is credible evidence that the prevalence 
of food allergies and celiac disease are on the rise 
globally, although there is great uncertainty about the 
magnitude of the rate of increase and the cause.  Part 
of the increase is likely due to increased consumer 
awareness of allergy and CD as well as more awareness 
and testing by doctors.  There is much misinformation 
about prevalence and people are often incorrectly 
96 Journal of Huazhong Agricultural University Vol. 33
diagnosed.  Many individuals reported being food 
allergic, but a clinical evaluation demonstrates they are 
not food allergic in many cases.  
The major risk for food allergy is acute, within 
minutes to hours after consumption of the allergenic 
food.  The primary risk of food allergy from GM crops 
is the potential transfer of a protein that already causes 
allergy in specific consumers.  If affected individuals 
consume a biotech crop that includes their allergen, 
reactions would likely be as severe as they would 
be to the natural source of the allergen.  Thus the 
primary concern for GM crops is to avoid the transfer 
of a protein that already causes allergy (of any kind, 
contact, airway or food) into a food grade plant of 
another species.  
7KH ,QWHUQDWLRQDO/LIH6FLHQFHV ,QVWLWXWH ,/6,
Allergy and Immunology Institute and the International 
Food Biotechnology Council organized discussions 
DQGDVHULHVRIVFLHQWL¿FSHHUUHYLHZHGSXEOLFDWLRQVWR
consider potential risks of food allergy from GM crops. 
The publications were presented in a special issue of 
Critical Reviews in Food Science and Nutrition (Vol. 
36, Supplement, 1996).  Panelists included scientists 
with expertise in biotechnology development and 
regulation or allergens and allergy. The first chapters 
explain allergy, food allergy, the biology of plant 
proteins the process of genetic modification of food 
plants and review allergenic foods known at the time. 
Two chapters provide the basis much of the background 
information that guided development of a science 
based assessment process to evaluate potential risks of 
food allergy for novel proteins[42-43].  The last chapter 
outlines an evaluation process to determine whether 
a protein expressed by a transgene would potentially 
present a risk of food allergy to consumers[40].  
The evaluation process outlined by Metcalfe et al.[40] 
was consistent with the FDA recommendations of 
DQGLQFOXGHGGHFLVLRQWUHHÀRZFKDUWEHJLQQLQJ
with evaluating the allergenicity of the source of the 
gene.  However, the decision tree did not exactly match 
the description in the text and some things were not 
clear.  Fig.1 represents my interpretation of the tree 
from the text[40]. If the gene is from a clearly defined 
allergenic source (food, airway or contact allergen), 
the next step would be to obtain sera from 14 humans 
allergic to the source and test for IgE binding to the 
GM protein using standard laboratory test methods. 
If fewer than 5 allergic donors are found for the test, 
then the protein is evaluated for stability to digestion 
by pepsin. All proteins regardless or source should be 
evaluated by sequence comparison to known allergens 
and a list of known food and respiratory allergens 
known in 1995 was included[40]. They recommended 
using FASTA to align the protein to known allergens 
and search for any contiguous 8 amino acid segment 
having an identical match to any allergen.  In practice 
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most bioinformatics matches were simply performed 
by a sliding “WORD” match of 8 amino acids.  If the 
protein matches an allergen, sera from humans allergic 
to the source of the matched allergen would be tested 
for binding. If IgE from appropriately diagnosed 
allergic serum donors clearly binds to the protein, the 
developer is likely to stop development and not submit 
the dossier to regulators.  However, if they would try 
to continue, the regulator would likely demand foods 
made from that GM event would have to be labeled 
as to the source to alert allergic subjects to avoid the 
food.  In the case of inconclusive IgE binding, subjects 
allergic to the source would be tested by skin prick 
tests (SPT) with the protein and if all are negative, they 
would be asked to undergo a double-blind, placebo-
controlled food challenge (DBPCFC), under ethical 
panel approval.  In addition, the protein would be 
tested for stability in acid with pepsin (protease) and 
the time of disappearance would be graded to evaluate 
digestibility.  The protein might be tested following 
W\SLFDOIRRGSURFHVVLQJPHWKRGVIRUWKDWVSHFL¿FFURS
to determine if it denatures.  However, processing 
stability is really only useful to understand if a risk of 
allergy or toxicity can be mitigated by normal food 
processing, similar to the inactivation of natural lectins 
and protease inhibitors in legumes during cooking. 
If the protein is stable to digestion by pepsin, the 
regulatory agency would be consulted for any requests 
for additional tests. 
Most GM events and newly expressed proteins 
approved in the US meet the criteria for minimum risks 
regarding the allergenicity evaluation presented by 
Metcalfe et al.[40] and the Codex[1].  A literature search 
¿QGVRQO\RQHSRWHQWLDO*0FURSSURGXFWWKDWGLGQRW
fit the history of safe use and upon testing for serum 
IgE binding using samples from the at-risk population 
of Brazil nut allergic subjects was found to bind 
IgE[39].  That potential product was not submitted to 
regulators and was terminated by the developer (Pioneer 
Hi-Bred).  No currently approved product that I am 
aware of received a gene from a commonly allergenic 
organism.  Thus the Brazil nut 2S albumin is the only 
one that would have presented a major risk of food 
allergy to a subset of consumers.  
2.4 Bioinformatics for matches to allergens
In addition to evaluating the source of the gene the 
bioinformatics search for identity matches between 
the GM protein and any known or suspected allergen 
has become probably the most important tool to 
identify possible risk and a reason to do serum IgE 
testing[38,44-45]. The Codex[1] document calls for a FASTA 
RU%/$673VHDUFKZLWK WKHDPLQRDFLGVHTXHQFHRI
the GM protein against a database known allergens. 
The www.Allergenonline.org database is the most 
comprehensive peer-reviewed allergen database that 
I am aware of.  The criteria of greatest emphasis is 
any match >35% identity over any segment of 80 or 
more amino acids.  The Allergen Online database 
(www.AllergenOnline.org) was established in the 
Food Allergy Research and Resource Program at the 
University of Nebraska in 2004 and implemented 
an expert review process.  It is updated annually to 
provide a curated database and search algorithms for 
risk assessment of allergenicity using bioinformatics 
tools[44].Version 14 of the database was released in 
January, 2014 and includes 1 706 sequences from 645 
protein-taxonomic groups representing 290 species. 
In my opinion the search for >35% identity over any 
segment of 80 amino acids is quite conservative as 
described in a number of publications.  There is little 
evidence of in vitro cross-reactivity for proteins sharing 
less than 45% identity by overall alignment (full-
length). And in terms of shared allergic reactions due 
to cross-reactivity, very few proteins sharing less than 
50% overall identity matches are cross-reactive[46]. 
Since 1996 there have been a number of scientific 
consultations and recommendations for “improving” 
WKHDOOHUJHQLFLW\DVVHVVPHQWRI*0FURSV7KH)$2
WHO expert panel review[47] suggested including a 
QXPEHURIFKDQJHVWKDWZHUHQRWYDOLGDWHG7KH)$2
:+2UHFRPPHQGDWLRQZDVWRXVH)$67$RU%/$673
to identify any segment of 80 or more amino acids 
ZLWKDQLGHQWLW\PDWFKRI!DQGWRVHDUFKIRUVKRUW
identity matches of six contiguous amino acids (aa) 
rather than eight aa suggested by Metcalfe et al.[40].  But 
those precautionary criteria have not been validated. 
They were reviewed in previous publications[3,38,45].  A 
number of studies demonstrated that searches for six 
aa identity matches produce far more false positive 
matches than true positives. The eight aa matches 
are better, but still do not have a high predictive 
value.  Others have also described the 80 amino acid 
VHDUFKHVDVEHLQJRYHUO\FRQVHUYDWLYHKRZHYHU,KDYH
not identified many probable false positives using 
that criterion, but also did not miss any likely cross-
reactive protein pairs[45].  There is some disagreement 
about the optimum algorithm for the 80 amino acid 
search as some bioinformaticians suggest searching 
IRU WKHEHVWRYHUDOODOLJQPHQWE\)$67$RU%/$673
and then scoring the best match as a more reliable 
alternative[48-50].   Recently the European Food Safety 
Authority (EFSA)[51] dropped the recommendation 
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to search for short, contiguous identity matches and 
the European Commission[52] accepted that advice 
in dropping it from their regulations.  There have 
been a few instances where short contiguous identity 
matches that occur by chance (no evidence of overall 
sequence homology), have led to requirements for 
serum IgE tests that were not needed[53].  There is a 
risk in performing such tests as in vitro IgE binding 
results can be ambiguous, with false positive binding 
that may inappropriately implicate a protein as a 
possible allergen[54]. Although there is little relevance 
of IgE binding to a single short segment of two non-
homologous proteins means a risk of allergy in that 
situation is unlikely, some regulatory bodies would 
want the developer to continue the investigation and 
possibly demand in vivo testing in humans.  
2.5  Serum IgE testing
Serum IgE tests are rarely warranted for evaluating the 
potential allergenicity of GM proteins.  However, if 
serum IgE testing is warranted the assays must be well 
designed, the methods should be validated with known 
allergens for the allergic serum donors and the test 
subjects should be demonstrated to have the appropriate 
IgE sensitivities. Test materials should include 
SXUL¿HG*0SURWHLQSXUL¿HGDOOHUJHQLFWDUJHWHJWKH
VHTXHQFHPDWFKHGDOOHUJHQDQGWKHVSHFL¿FLW\RIDQ\
IgE detection antibody must be verified, appropriate 
blocking solutions are needed. In some cases specific 
inhibition assays may be required.  Critical factors in 
materials and assay design are presented in a number 
of publications[45,54-55]. If the protein may contain 
asparagine-linked carbohydrates, there is the possibility 
the plant might modify the protein with the addition 
of alpha-1,3 fucose or beta-1,2 xylose on the stem of 
the asparagine-linked glycan may bind IgE from many 
subjects, but there is little or no evidence for clinical 
reactivity[56-57].  Those structures are known now as 
cross-reactive carbohydrate determinants (CCD). If 
there is a signal peptide and an N-linked sequon (Asn-
[7KU6HUWKHSURWHLQVKRXOGEHWHVWHGIRUWKHSUHVHQFH
of CCD. Inhibition studies may need to be performed 
to evaluate the relevance of any in vitro IgE binding. 
If there is evidence of IgE binding in vitro and there is 
a desire to continue with development of the product, 
the biological relevance of binding may be tested using 
basophil activation or basophil histamine release[58]. 
Alternatively, skin prick tests (SPT) or double-blind, 
placebo-controlled food challenges may be required 
using highly characterized test materials and subjects 
who are well informed and have consented to the 
challenge.
2.6  Potential de novo sensitization: stability in 
pepsin and abundance
If there is no evidence the protein is likely to be an 
allergen based on source and a lack of bioinformatics 
match, there is no justification for performing serum 
IgE tests.  There is a low probability of risk and there 
is no at-risk population.  The only other questions 
regarding allergenicity are whether the protein 
might sensitize de novo.  As suggested by Metcalfe 
et al.[40], proteins that are stabile in pepsin in an in 
vitro digestion assay and are abundant, have a higher 
probability of being an important food allergen. 
However, the correlation is modest even though many 
major food allergens are stable or fractions of the 
protein are stable and abundant[59].  The correlation of 
stability in pepsin has been performed at pH 1.2 and 
DQG WKH)$2:+2 UHFRPPHQGDWLRQZDV
to use both conditions to evaluate stability.  We did 
not find any significant difference[59].  The EFSA[57] 
recommendation was to use more “physiological” 
pH (3.5), but that has the effect of markedly reducing 
pepsin activity and has not been investigated in terms 
of predictive value.  The FDA continues to accept the 
use of either pH 1.2 or 2.  There is also not a consensus 
on abundance although it is clear that the abundance 
of a number major allergenic proteins in plants used 
for foods is greater than 1% of the protein in the food 
fraction[60].
Most of the GM proteins have been found to be 
digested rapidly in pepsin at pH 1.2 or 2.  However, 
the Bt protein Cry9C that was originally introduced 
into corn to protect against the European corn borer 
moth larvae by Plant Genetic Systems (PGS) in Ghent, 
Belgium was found to be quite stable in pepsin. The 
SURGXFWZDVFDOOHG6WDU/LQNFRUQ7KHFRPSDQ\ZDV
purchased by AgrEvo, then Aventis CropScience which 
was finally acquired by Bayer CropScience.  Food 
approval was withheld because the protein was stable 
in the pepsin digestion assay (described later) and 
regulators felt there was some risk the protein might 
eventually sensitize someone, predisposing them to 
DOOHUJLFUHVSRQVHVWR&U\&6WDU/LQNFRUQZDVJURZQ
on ~ 122 000 hectares in the US in 1999, and some 
grain from the corn was accidentally, but illegally 
included in some human food products (corn chips and 
taco shells).  Tests by an anti-GM NGO discovered the 
LQFOXVLRQRI6WDU/LQNFRUQHYHQWLQVRPHIRRGSURGXFWV
and notified the US government and news media. 
Interestingly the question was whether people might 
become allergic to the protein, which would take time 
to sensitize people.  There is no indication that people 
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were pre-exposed to Cry9C, so sensitization would 
have been from exposure in the contaminated taco 
shells and chips. However, within two weeks of the 
announcement more than 100 consumers complained 
they had experience food allergic reactions following 
consumption of taco shells or corn chips.  Since corn 
is one of the least allergenic of grains and the quantity 
of Cry9C was quite low in corn grain and the grain 
was grown for only one year, it is highly unlikely that 
anyone was sensitized to the protein.  However, the 
Center for Disease Control of the US investigated 
each consumer report.  Those individuals who claimed 
reactions that might be consistent with food allergy 
were asked if they would provide blood samples and 18 
did[61] 1RQHRIWKRVHLQGLYLGXDOVKDG,J(VSHFL¿FIRU
Cry9C[61].  Since the grain and corn seeds were released 
and in food without approval, the US government 
demanded recalls and monitoring.  Foods, ingredients 
and corn seed were screened and those containing 
the Cry9C protein or the transgene were pulled from 
the market.  It took six or more years to completely 
remove all traces of Cry9C from seed and grain stores. 
There have been rough estimates that total costs for 
removal may have exceeded $500 million.  Yet we 
should remember that there is no proof that anyone 
was harmed by consuming Cry9C.  There is clearly a 
different level of risk of allergy that might be present 
IURPD*0IRRGFURSVXFKDV6WDU/LQNWKDQZRXOGEH
associated with an outbreak of Norovirus, hepatitis or 
E. coli O157. We might conclude that the regulatory 
response was not in proportion to the risk in the case of 
6WDU/LQN+RZHYHUWKHDELOLW\WRUHPRYHD*02IURP
SURGXFWLRQZDVGHPRQVWUDWHGE\WKHUHFDOORI6WDU/LQN
corn and it shows that you can remove a GMO from 
the agricultural and food system if there is a reason to 
do so.  It just takes time and an enormous amount of 
money.  
Another product that is not as rapidly digested in 
pepsin as Cry1Ab (in corn) or CP4 EPSPS (in herbicide 
WROHUDQW VR\EHDQVDUH WKH WZRSURWHLQV &U\$E
Cry35Ab1) in another insect protected corn event. 
The proteins have intermediate stability as reported by 
Dow, the developer[62]. The EPA did allow this product 
into the market as the abundance of the proteins is low 
in grain and the stability intermediate.  
New proteins expressed in the GM crops approved 
so far have been expressed and accumulate at low 
levels in the food materials of the crop, often in the 
range of or less than a few micrograms per gram dry 
ZHLJKWRIVHHG&(5$*0&URSGDWDEDVHKWWS
FHUDJPFRUJLQGH[SKS*0&URS'DWDEDVH). Thus all of 
the GM proteins accumulate at levels markedly below 
the concentration of most of the important dietary 
allergens (typically >1% of total protein). 
There is no published evidence that an approved 
GM crop has caused allergies due to the presence 
of the transgenic protein.  A study was performed to 
determine whether soybean allergic subjects might 
have IgE binding to the CP4 EPSPS enzyme that was 
introduced into soybean to provide tolerance to the 
herbicide glyphosate[55]. This was not a regulatory 
study, but was performed as a stewardship study to see 
if there was any evidence of sensitization years after 
the product entered the market.  Serum samples were 
collected from soybean allergic subjects in Europe and 
South Korea and tested using common protocols and 
highly characterized test materials. The study did not 
¿QGHYLGHQFHRI,J(ELQGLQJWRSXUL¿HG&3(3636RU
to the protein in extracts of GM soybeans[55].  
2.7  Potential improvements for evaluating IgE 
mediated allergenicity
7KH)$2:+2SDQHO[47] recommended using targeted 
human serum testing in an attempt to determine 
whether a protein that is not similar to any known 
allergen might pose a risk due to existing sensitization 
or cross-reactivity.  Targeted testing was defined as 
in vitro IgE binding tests using sera from 50 subjects 
with allergy to sources that are broadly related to 
the source of the transferred gene.  For genes from a 
dicotyledonous plant, individuals allergic to one or 
more other dicot species would be used for serum 
testing.  There was an exemption for proteins from 
bacteria since there are almost no allergies to bacteria. 
The targeted serum testing has never been tested in a 
way that would demonstrate its predictive power and it 
is counter-intuitive based on our knowledge of cross-
reactivity.  Homologous proteins from even moderately 
related sources (family level) are rarely cross-reactive 
by in vitro tests and clinical reactivity is rarely shared. 
The only proteins that are so broadly cross-reactive in 
laboratory tests are profilins, PR-10 proteins (Bet v 1 
homologues), lipid transfer proteins and tropomyosins 
from crustaceans and other invertebrates. Those are all 
HDVLO\LGHQWL¿HGE\ELRLQIRUPDWLFV  7KH86GRHVQRW
recognize targeted serum testing as a useful tool for the 
assessment of novel proteins.
7KH)$2:+2[47] also recommended performing 
sensitization tests using two species of animal models, 
or two routes of sensitization in one species to evaluate 
the allergenic potential of each new protein.  While 
many laboratories have tested various animal models in 
an attempt to predict the allergenicity of proteins, there 
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are none that have proven predictive over a wide range 
of effective allergenicity (from mild or non- to strongly 
DOOHUJHQLFDVUHYLHZHGE\/DGLFVHWDO[63]. There has 
been research that shows some promise for evaluating 
mechanisms of allergy and immunotherapy[64] and for 
preliminary ranking of allergenic sources[65-66].  A few 
have tested purified or partially purified proteins[67], 
but have not been validated to rank new proteins in 
the context of potency or prevalence of allergens in 
the human population[63].  The US does not recognize 
animal models as being useful at this time for 
predicting the allergenicity of novel proteins.
The  Codex  gu ide l ine  d id  inco rpora t e  t he 
recommendation for testing the sequences using the 
)$67$RU%/$673 VHDUFK DOLJQPHQWV WR LGHQWLI\
matches of >35% identity over any segment of 80 or 
more amino acids.  Codex[1] also retained the language 
suggesting the use of a short identity match of 6 or 8, 
but suggested the evaluator must justify that choice. 
The US regulators now expect a comparison for 
identifying matches with >35% identity over 80 amino 
acids using a comparison like that available on www.
AllergenOnline.org or a full-length comparison by 
%/$673ZLWKHYDOXDWLRQRIDOLJQPHQWV WRPHHW WKH
same criterion.  They do not seem focused on short-8 
amino acid matches, but most (all?) developers have 
supplied that data. 
The EC regulation[52], which was based to a large 
extent on recommendations from another expert 
panel review process by the EFSA[51] also includes a 
number of suggestions for unproven tests including: 
HYDOXDWLRQRISRWHQWLDODGMXYDQWLFLW\RIWKHQHZSURWHLQ
the use of proteomics to consider possible changes in 
the expression of endogenous allergenic proteins for 
FRPPRQO\DOOHUJHQLFVSHFLHV HJVR\EHDQSHDQXW
and the use of more physiological pH (3.5) for the 
pepsin digestion assay.  Yet those test methods have not 
been validated to demonstrate they would improve the 
risk assessment and are not asked for by US regulators. 
The US regulators do not ask for additional tests such 
as potential adjuvanticity unless there is information 
that would reasonably support the hypothesis that 
a new protein may be a lectin or have some other 
adjuvant-like properties.
2.8  Celiac disease
Risks related to CD have only been found to involve 
certain glutens (gliadins and glutenins) from wheat 
and near wheat grain relatives.  Codex[1] recommends 
and the US government would require an evaluation 
if a gene from wheat, barley, rye or possibly oats, 
is transferred into another species, such as corn, 
rice, or sorghum.  As far as I know, no developer 
has submitted a potential product to US regulators 
using such a construct.  While the Codex demands an 
evaluation for proteins from wheat or wheat relatives, 
they have not provided guidance on the process.  My 
laboratory considered the problem in the context of 
what is currently known about CD and the glutens 
involved in and developed a celiac database to provide 
a bioinformatics tool to allow rapid identification of 
potential hazardous proteins.  In order to develop the 
tool we reviewed published scientific information on 
CD. 
Symptoms of malabsorption and diarrhea associated 
with diet of bread were first described nearly 2 000 
years ago in medical writings from Greece[68].  But 
it wasn’t until 1888 that a physician in the United 
Kingdom (UK) gave the name coeliac (or celiac) to 
those suffering intestinal distress associated with eating 
foods containing wheat.  Those observations were lost 
on modern medicine until 1952 that physicians in the 
UK published descriptions associating the wasting 
and intestinal pathology with the consumption of 
wheat.  In the 1990’s gastroenterologists developed 
methods for endoscopy and developed antibody tests 
that demonstrated patients with CD were developing 
antibodies that bound to connective tissue in the 
intestine and had T cells that were activated upon 
binding wheat peptides from glutens in the context 
of specific major histocompatibility antigen resenting 
UHFHSWRUV5HFHQWVWXGLHVKDYHLGHQWL¿HGPDQ\SHSWLGHV
from glutenins and gliadins of wheat, barley and rye 
grains that are responsible for activating T cells in 
genetically susceptible individuals[30, 69]. As many of 
these discoveries were occurring in the mid-1990’s 
and beyond, the evaluation of proteins in wheat, barley 
and rye that might be responsible for causing the T 
FHOOVSHFL¿FUHVSRQVHVLQWKHIUDFWLRQRIVXEMHFWVZLWK
the correct MHC Class II for susceptibility (MHC 
DQ 2.5 and MHC DQ 8) were just emerging.  Since 
WKHQPDQ\VWXGLHVKDYHEHHQSXEOLVKHGWKDW LGHQWL¿HG
peptide sequences that are responsible for binding to 
the right MHC and activating effector T cells in those 
with CD have emerged.  While the Metcalfe et al.[40] 
and the Codex[1] recommendations do not recognize 
the predictive capabilities of bioinformatics to evaluate 
risks of celiac disease from wheat subfamily proteins, 
it is clear that a substantial number of proteins were 
being identified that might serve as a database of 
“risky” proteins. Metcalfe et al.[40] and the Codex[1] 
both suggest that genes taken from wheat or wheat 
relatives that encode proteins should be evaluated for 
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their potential to cause CD, they did not specify how. 
In 2011, Plaimein Amnuaycheewa, a PhD graduate 
student in my laboratory reviewed more than 50 
available publications identifying peptides involved 
in T cell reactivity using cell samples from celiac 
patients and we developed a database of peptides that 
can be used to screen potentially hazardous peptides 
from proteins from the wheat and wheat relatives. 
We have constructed a database of peptides from 
wheat, barley and rye that cause T cell stimulation or 
intestinal epithelial pathology (www.allergenonline.
RUJFHOLDFKRPHVKWPO7KHGDWDEDVH LV SDUW RI WKH
www.AllergenOnline.org database for bioinformatics 
evaluation of potential IgE mediated allergenicity for 
GM proteins.  Currently it includes 1 016 peptides with 
published evidence of T cell reactivity using cells from 
CD patients in the context of MHC Class II DQ 2.5 
or DQ8, or toxic effects in intestinal epithelial cells or 
pathology in intestinal villi from those with CD.  The 
amino acids of proteins introduced into GM crops may 
be searched for exact matches to the peptides in the 
database, or the proteins can be searched by FASTA 
for meaningful matches to 68 whole proteins known 
to stimulate CD, using criteria of >45% identity over 
alignments of at least 100 amino acids as potentially 
stimulating CD. A total of 53 references are included 
to explain the selection of peptides and proteins that 
might cause CD in susceptible individuals.  Similar to 
the allergenicity assessment, bioinformatics methods 
should are able to identify proteins that might represent 
a modest to clear risk of causing disease. If there is 
a desire to introduce a wheat sub-family protein into 
another crop e.g. rice or eggplant (brinjal), the amino 
acid sequences there should be screened using this 
database to consider risk.  If a positive match is found, 
the protein should be tested using cells or challenges in 
CD subjects to evaluate risks using cell based assays or 
possibly food challenges in at least 10 consenting CD 
subjects to ensure minimal risk to the CD population as 
the “at-risk” group of consumers. The bioinformatics 
criteria we believe is predictive based on extensive 
simulations is any 100% identity match to one of the 
1 016 peptides or a FASTA match of >45% identity 
with any segment of 100 aa or more having an E 
score of < 1x 10-15.  Genes taken from plants outside 
of the Pooideae subfamily of grasses represent little 
risk of causing CD and therefore even if they are 
homologues of glutens that cause CD, they are highly 
unlikely to result in disease.  Proteins that do not 
exceed these criteria should present little or no risk of 
inducing CD.
2.9  Potential toxicity
Few proteins are toxic when consumed and most of 
those act acutely (e.g. ricin)[70].  The HOSU evaluation 
is a key consideration in addition to a bioinformatics 
comparison of the amino acid sequence of any newly 
expressed protein to the NCBI protein database using a 
keyword limit of “toxin” or “toxic”. Although it seems 
there is a lack of published data on how to perform a 
bioinformatics evaluation for potential toxicity for a 
GMO, all GM products submitted to the US FDA or 
EPA must undergo an evaluation[71].  I have performed 
the bioinformatics searches for a few potential GM 
crops and novel food ingredients for regulatory 
submissions using the general NCBI protein database 
XVLQJ%/$673ZLWKNH\ZRUGOLPLWVRIWR[LQRUWR[LFWR
focus on potential risks.  Usually additional sequence 
comparisons are needed using the new protein in the 
search but without keyword limits to provide a relative 
comparison of other proteins with a known history 
of safe use or safe human exposure and the query 
protein (GM protein) or novel food ingredient.  The 
process also requires a careful evaluation of published 
scientific literature related to the closest sequence 
matched proteins as well as the protein of interest. 
While bioinformaticians often claim that proteins 
sharing greater than 25% identity over their full-length 
are homologues and often have similar functions, most 
proteins with such relatively low identities do not share 
VSHFL¿FWR[LFSURSHUWLHVRUH[DFWHQ]\PDWLFIXQFWLRQV
Therefore bioinformatics evaluations must be evaluated 
relative to other proteins.  The results should guide 
decisions regarding a need for any toxicology testing, 
and if needed, the target organs and tests that might be 
useful to evaluate risks.  So far there is no evidence that 
any protein introduced into a GM plant approved in the 
US has had a toxic effect of humans or other mammals.
In the US regulatory system, if a protein introduced 
into a GM crop is intended to have toxic activity to 
insects, bacteria, a fungus or have anti-viral activity, 
such as the plant incorporated pesticidal Bacillus 
thuringiensis crystal proteins, the proteins must be 
tested by an acute mouse toxicity test.  The OECD 
guideline for acute toxicity testing (E425, 2001) is 
the model followed in many studies.  The protein is 
gavaged into adult mice using a dose that is typically 
1 000 fold higher on a mg protein per kg body weight, 
expected for human food consumption.  Sometimes 
the excess dose is not quite so high, but normally 
at least 100 fold higher.  The dose is given on day 0 
and the health of the animals is monitored along with 
control (mock-dosed) animals for 14 days.  At that time 
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body weights, blood samples appearances and clinical 
observations are collected. The animals are euthanized 
and gross pathology and if needed histology samples 
are examined for abnormalities.  Usually there are 10 
animals per sex per treatment group. Quite often two 
doses are used as separate treatment groups to ensure 
that any abnormality has a dose-effect.  While there 
may be some statistically different findings for a few 
measurements between groups for the GM and control 
animals, historical weights and measures of the same 
strain of mice should be available for that specific 
toxicology facility to be able to evaluate unexpected 
differences.  Some studies describing the acute mouse 
toxicity tests for approval of some GM products have 
been published[72-74]. In rare circumstances longer term 
toxicology studies are called for by regulators or critics 
of the technology, but the scientific justification for 
extra testing is usually quite weak. It is important to 
consider that unlike a number of organic compounds or 
heavy metals, consumed proteins do not accumulate in 
the body of mammals and toxic effects are expected to 
be acute rather than chronic.  
Some countries (e.g. within the European Union) 
require an acute mouse test as well as a subchronic, 90-
day whole-food feeding study in rats, or repeat dose 
testing with high doses of whole protein. While the 90-
day study design is detailed in the OECD guidelines 
and a few published studies have been performed, there 
is not a good justification and little proof that such a 
study will identify known hazards[75].  The 90-day rat 
feeding study is more of a hybrid toxicology-nutritional 
study. Some regulators and critics suggest that the 
90-day study provides a tool to evaluate “unintended 
effects” that might arise due to the insertion site of the 
new gene into the genome of the crop.  It should be 
worth considering that the host (recipient) crops are 
normally species that have been consumed for centuries 
with good history of safety and that genetic variation 
in naturally bred varieties and lines have introduced 
many unintended genetic changes without introducing 
adverse toxic properties in the food.
Two studies designed to test the predictive value 
of the 90-day rat whole food feeding study using 
experimentally designed recombinant rice gave 
VRPHZKDWFRQÀLFWLQJUHVXOWV[76-77]7KH¿UVWWHVWHGD*0
rice expressing the snow-drop lectin from Galanthus 
nivalis (GNA) and the authors conclude that the study 
failed to show the potential toxicity of the lectin.  The 
second experimental GM expressed high levels of 
the common bean phytohemagglutinin lectin PHA-E, 
which did show toxicity when the protein was fed in 
raw form at high concentration.  My interpretation is 
WKDWWKHUDZXQFRRNHG3+$JDYHVLJQL¿FDQWWR[LFLW\DV
would be expected to occur in humans consuming raw 
kidney or navy bean.  The GNA study seems to have 
had negative results because the protein expression was 
too low in concentration or the protein was heated in 
feed preparation.  Since humans can consume cooked 
kidney and navy beans, but not raw beans, it seems the 
test results were predictive of the human experience. 
It might have been more appropriate to test raw and 
cooked samples as two separate treatments. The assay 
is not very sensitive and there are severe limitations 
to the dose that can be feed compared to the human 
diet, typically much less than the 100 fold safety factor 
typically used in toxicity studies.  Many toxicologists 
have questioned the usefulness of the 90-day whole 
food feeding study[9].  While others claim even more 
detailed, complex and expensive studies are needed to 
fully test potential toxicity[78].  However, a recent peer 
reviewed evaluation of published safety, toxicology and 
whole grain rat feeding studies on current GM crops 
provides objective evaluation of the overall approach 
and concludes that in most cases a 90-day feeding 
trial is not needed to evaluate safety, but results are 
certainly consistent with safety[79]. Interesting at a time 
when animal welfare groups and even the institutional 
animal care and use committees in many institutions 
are calling for reduced animal testing, some scientists 
involved in regulation or testing are calling for more 
unproven animal studies.  
2.10  Additional toxicology studies
Questions should be asked about any new proposed 
toxicity test, as well as existing testing methods.  What 
types of hazard can be or has been identified with a 
given test protocol? What is the rate of false positive 
and false negative results for each test? And finally, 
are there more effective tests that could be used?   A 
number of recent publications have discussed the 
pros and cons of using alternative computer based, 
cell-based, or tissue based methods, primarily for 
pharmaceutical toxicology evaluation[80-81]. They focus 
on having a scientifically sound hypothesis, validated 
methods and historical control data as essential criteria. 
Understanding the limitations and benefits of the 
different models are essential in making a determination 
about tests that might be useful for evaluating potential 
toxicity. In most countries including the US, there is a 
general requirement by animal care and use committees 
to show that the specific test on the specific test 
material has not been performed previously unless there 
is a reason to doubt the results. Therefore repeating 
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the same animal tests on the same GM crop event in 
multiple countries is deemed unethical. 
The final conclusion of toxicity evaluations should 
be either the GM crop does not pose any additional 
significant risk of toxicity compared to similar non-
GM varieties, or that it does pose a substantial new 
risk. The FDA and EPA have been able to reach 
those conclusions for many new GM products if the 
developer followed the standard assessment process. 
Unfortunately some regulatory bodies (e.g. EFSA and 
the European Commission) in Europe and regulators in 
India and China continue to raise new questions about 
hypothetical concerns including potential adjuvanticity, 
alteration of fertility or the potential to induce cancers 
even though there are very few examples that any 
dietary protein could have such an effect.  Those 
regulators then fail to approve products for which there 
is no evidence of risk. The US regulatory agencies have 
emphasized the need to use proven methods to evaluate 
safety of novel proteins and GM products.  They have 
not asked (so far) for additional studies that are not 
already demonstrated to help assess safety. However, if 
a developer provides data from a new evaluation, they 
will consider it, although it may delay approvals or 
acceptance.
3   Evaluting   GM  products for 
unintended   effects 
7KHPHWKRGVDQGJHQHWLFPRGL¿FDWLRQVXVHGWRJHQHUDWH
the herbicide tolerant or insect protected traits that have 
been widely adopted following regulatory approvals 
introduce relatively minor variations in the host 
plant genomes compared to those introduced through 
“natural processes” of mutations and reproduction. 
Interestingly those “unknown” natural changes are not 
characterized except by phenotypic variation and they 
have evolved to provide the diverse genetic background 
needed to allow plant survival with challenges of 
plant diseases and pests, and diversity of climactic 
conditions and soils. The GMOs on the other hand have 
been characterized in insertion site, copy number, gene 
sequence and encoded products.  If the introduced gene 
encoded an enzyme, metabolites of the enzyme would 
have to be evaluated.   Interestingly, a good portion of 
WKHPDL]H=HDPD\VJHQRPHLVPDGHDQGPRGL¿HGE\
transposons that were described as “jumping genes” by 
Barbara McClintock from her studies in 1948.  She was 
awarded the Nobel Prize in Physiology in 1983 for that 
discovery[82]. A recent study identifying genes in 503 
genetically diverse lines of maize found ~ 16% of the 
genes are not present in all 503 lines, showing marked 
genetic variation[83].  The bread wheat we consume 
today (Triticum aestivum) is encoded by three sets of 
chromosomes (thus is an evolutionary hexaploid) of 
relatively primitive grass species so that most proteins 
in wheat are encoded by three sets of divergent genes 
that are nearly identical in some cases, or very different. 
In addition, the replication of genomes through 
sexual reproduction allows gain or loss of function 
and extension of the capacity of the plant to grow in 
different environments or have multiple options for 
nutrients (or anti-nutrients).  Bread wheat and pasta 
wheat (Triticum durum or Triticum turgidum subsp. 
durum, an evolutionary tetraploid) are both nutritious 
and used extensively in human food. But both cause 
celiac disease in about 1% of the general population 
in North America and Europe, genetically susceptible 
individuals (25% of the population) and IgE mediated 
food allergy in a much smaller number of people (<0.4% 
of the public).  Those are non-GM crops as there are 
no approved GM wheat varieties (yet).  That illustrates 
that all foods represent some risks for some consumers 
and that it is necessary to have genetic variation to 
produce the foods we eat.     
We should step back and consider why we eat 
certain foods like rice, wheat, soybeans and maize and 
other foods, but as humans we do not eat grain alone. 
Humans have selected certain food sources for ease of 
production but mostly for nutritional value, measured 
by average energy, amino acid composition, lipid 
content, carbohydrates, vitamins and minerals.  Those 
crops were initially grown and consumed long ago 
and dramatically changed by breeding and cultivation 
ZLWKRXWDQ\VFLHQWL¿FPHDVXUHRIVSHFL¿FDPLQRDFLGV
FDORULFGHQVLW\YLWDPLQVRUIDWW\DFLGSUR¿OHV ,QWKH
past 100 years we have learned how to measure those 
components and also in many cases believe we know 
what a “healthy” and “nutritious” diet is made up 
of.  Typically it is a mixture of different foods.  Even 
though we have all that information today we do not 
make detailed measurements of the composition of 
every shipment of grain that goes into a box of cereal 
or a loaf of bread because would cost too much and 
we also know that on the average safety and nutrition 
of the cereal or bread is fine. We have learned the 
primary components of each major food crop and have 
typical measurements that are tested by agricultural 
nutritionists to ensure they formulate optimal diets for 
DJULFXOWXUDOO\LPSRUWDQWVSHFLHV(DFKFURSKDVVSHFL¿F
components that are evaluated, and nutritionists have 
ranges that they deem acceptable for animal feed.  
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3.1  Key nutrients and anti-nutrients
Key nutrients and anti-nutrients expressed in the 
host plant (gene recipient) are to be measured and 
evaluated relative to non-GM varieties or lines 
intended for the same uses.  There is an expectation 
that the key components will fall within the range 
the same components in non-GM events of similar 
genetic background[84-85].  But as with all statistical 
PHDVXUHVVWDWLVWLFDOO\VLJQL¿FDQWO\GLIIHUHQWYDOXHVDUH
expected when measuring many components. However, 
statistical differences alone are not a reason to reject a 
SURGXFWDVXQVDIHWKHUHVKRXOGEHDVFLHQWL¿FDOO\EDVHG
rationale to suggest potential harm. In order to provide 
guidance on appropriate compositional traits for given 
food crops recent historical records for varieties of the 
same crop must be found or a number of commercial 
varieties must be planted in adjacent plots in multiple 
¿HOGWULDOV
Animal nutritionists understand the differences in 
compositional measurements that are important for 
canola, corn, cotton, potatoes, soybeans and wheat. 
And many possible compositional measurements are 
irrelevant to the typical use of these crops. However, 
some GMO regulators and cri t ics expect that 
developers will measure every possible component 
of the GMO and compare it to the nearest genetic 
UHODWLYH,IWKHUHDUHVWDWLVWLFDOO\VLJQL¿FDQWGLIIHUHQFHV
some would argue it is due to the insertion of the DNA 
and that the food is unsafe. Yet we have also learned 
that plants from genetically identical plants grown in 
close proximity or 100 miles apart can differ in many 
components due to micro-environmental differences. 
The complexity of the genotype and environmental 
interactions that can lead to significant differences 
in expression of some components of agriculturally 
important crops has not been sufficiently evaluated 
in terms of biological relevance, yet some scientists 
are calling for increasing the use of various omics-
techniques to measure variation with high precision 
(Doerrer et al., 2010).  Fortunately, even though the 
compositional analysis is considered an important part 
of the safety assessment of a GM crop, in the US and 
most countries regulators have not blocked an approval 
of a GM food or feed crop due to minor statistical 
variations in composition as it is clear that non-
GM products often have fairly marked differences in 
components without measurable effects on food or feed 
VDIHW\3ULYDOOHHWDO$QLPSRUWDQWUHFHQW¿QGLQJ
by two different groups is that compositional differences 
between GM and near-isogenic lines are primarily due 
to back-crosses and conventional breeding and are not 
caused by insertion of the gene[86-87].  Understanding the 
source of variation is an essential consideration as some 
authors are suggesting complex proteomics analysis 
of potential differences in endogenous allergen levels 
in GM plants might be due to insertion and require 
additional tests[88]. 
Thus we need further definition of the important 
components to measure and guidance on the variation 
of those components that may have biological 
relevance.  In order to provide some references for 
composition, the biotechnology industry supports 
WKH ,QWHUQDWLRQDO/LIH6FLHQFHV ,QVWLWXWH ,/6,&URS
Composition Database[89] that contains compositional 
data for seed of corn, cotton and soybeans (KWWSV
ZZZFURSFRPSRVLWLRQRUJTXHU\LQGH[KWPO). The data 
is limited to years 1995-2005 and specific countries 
RIFXOWLYDWLRQ7KH ,/6,GDWDEDVH LV VFKHGXOHG WRD
new version released by the end of 2014 that will 
include many more data-points and expand to include 
sweet corn, canola and rice. Additional information 
is available for rice and soybeans from a Japanese 
composition database (KWWSDIGEGFDIIUFJRMSDIGE
LQGH[BHDVS). The data is available for a limited set 
of varieties of these two crops and limited years of 
cultivation from Japan[90].  These databases provide 
some information about methods and ranges of 
components specific for the species. Interestingly the 
animal feed industry is most sensitive to changes in 
composition of commodity crops as slight variation in 
feed quality can mean profit or loss to major animal 
producers.  Companies like Tyson (USA), with more 
than 4 000 poultry farms in chicken production 
and Perdue Farms (USA), second leading poultry 
producer in the US measure composition of feed 
based on nutritionally important ingredients that 
are crop-specific.  In order to formulate optimum 
feed for growth and safety they measure proximate 
analysis of every delivery of commodity crop getting 
random representative samples from their extremely 
large shipments, measuring total protein, lipid, 
FDUERK\GUDWHVPRLVWXUHDVK¿EHUDQGRIWHQWKHDPLQR
DFLGFRPSRVLWLRQDVZHOODVFURSVSHFL¿FYLWDPLQVIDWW\
acids and minerals.  They also measure crop specific 
toxicants and anti-nutrients. The poultry industry is 
the most sensitive to nutritional quality changes.  In 
addition, every shipment of corn grain or dry distiller’s 
grain is checked for mycotoxin levels as corn is the 
most likely crop to have contamination. An example 
of a chicken broiler study on a GM stacked-trait event 
describes the feed ingredient evaluations and provides 
real data that would be similar to the analysis performed 
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by Tyson or Perdue[91].  The major components and 
measures essential to optimum chicken growth that are 
evaluated in feed preparation do not include a long list 
of metabolites, RNA transcripts or proteomic measures. 
Instead they focus on components that are known to 
contribute to the substantial growth rate (approximately 
a 35-fold increase in body weight from hatching 
through day 42 of the studies) for the chickens. The 
feed efficiency and weight gain are highly correlated 
to nutritional properties, more so than any other 
animal species.  The production of feed lot size and the 
number of animals in commercial production units is 
normally quite large.  Since chickens are fed defatted 
soybean meal, the composition of fatty acids and lipids 
is not as critical for soybean ingredients as it is for 
mammalian species, such as dairy cows.  Most dairy 
farms, beef, pork, goat and sheep operations do not 
monitor every shipment of feed, except for mycotoxins 
in corn, but instead sample occasionally throughout 
the year to re-formulate diets if the typical component 
nutritional values are changing. In the US studies 
supplied to regulatory agencies include proximate and 
specific ingredient measures comparing the new GM 
line ingredients (seeds, grain or forage) and ingredients 
from a nearest genetic comparator of non-GM line and 
ingredients from three to five other commercial non-
GM lines, all grown at multiple geographical sites 
to provide environmental diversity for plant growth. 
Some countries But in general a GMO developer 
must provide specific composition to regulators from 
multiple years of multiple geographical replicates of 
the GMO and a number of non-GM comparators to 
allow statistical comparison.  The relevance for safety 
is usually not clear. 
In addition to nutrients, specific anti-nutrients are 
DOVRPHDVXUHGWKDWDUHFURSVSHFL¿F LQFOXGLQJOHFWLQV
and trypsin inhibitors, toxins such as solanine and 
allergens for highly allergenic crops (e.g. soybean). 
While there are generally accepted limits for many 
anti-nutrients (e.g. solanine at 200 mg per kg fresh 
weight, Friedman, 2006), acceptable limits of variation 
allergens have not be established[92].
3.2  Measuring potential changes in endogenous 
allergen levels 
There is a requirement in the US and a recommendation 
by the EU to consider whether insertion of the 
transgene has increased the expression or accumulation 
of naturally occurring endogenous allergens if the 
gene recipient (host plant) is a common source of 
food allergy.  Regulators recognized that the risk of 
food allergy is not equal from different allergenic 
VRXUFHV /DEHOLQJUHTXLUHPHQWV IRUSURFHVVHGIRRGV
are meant to be truthful and to protect those at risk. 
In the US and in the EU food labeling regulations 
demand that all ingredients derived from the major 
allergenic sources must be labeled.  That list includes 
the eight common allergenic food in the US: chicken 
eggs, cow’s milk, peanut, many tree nuts, crustacean 
shellfish, fish, soybeans, wheat (KWWSZZZIGDJRY
IRRGUHVRXUFHVIRU\RXFRQVXPHUVXFPKWP). 
In addition in the US foods containing glutens from 
wheat, barley and rye must be labeled, unless the 
gluten content is less than 20 ppm on a mass basis. In 
the EU six more foods are added to the list of eight 
including: cereals containing gluten (wheat, rye, barley, 
RDWVVSHOWNDPXWDQGK\EULGVRIWKRVHJUDLQVFHOHU\
(root), mustard seed, sesame seed, lupin and molluscs 
as well as sulphur dioxides)  as be listed all whole, 
relatively unfractionated ingredients must be labeled as 
to source (e.g. wheat, eggs, milk). In both the US and 
EU ingredients derived from the commonly allergenic 
foods must also be labeled unless the processed 
LQJUHGLHQWLVH[HPSWHJKH[DQHUH¿QHGVR\EHDQRLO
Starch from wheat must be labeled as coming from 
wheat, but starch from corn, rice or tapioca may simply 
be labeled as modified starch, without indicating the 
source. Thus in the US and EU a developer must 
evaluate potential changes in endogenous allergens in 
GM peanuts, soybeans and wheat, but not in common 
beans (Phaseolus vulgaris), corn and rice as they are 
not common sources of allergy.  The methods used to 
perform the evaluation have generally been consistent 
with measurements of allergens in diagnostic allergen 
products[93-94]. Pharmaceutical grade allergen extracts 
are expected to show similar qualitative binding using 
immunoblots as well as variation in total IgE binding 
between 50% and 150% of the extract standard mean 
serum IgE binding using pooled allergic sera to 
compare one batch of allergen extract to a previous 
batch[93,95]7KH¿UVWKHUELFLGHWROHUDQWVR\EHDQHYHQW
40-3-2 from Monsanto) was tested for differences in 
IgE binding using western blots of soybean extracts 
separated on SDS-PAGE with sera from three 
individual soybean allergic subjects[96].  Sten et al.[97] 
performed a much more extensive, non-regulatory 
study of IgE binding by in vitro methods using sera 
from 10 soybean sensitized subjects to compare results 
between 10 genetic varieties of the same GM event 
(40-3-2) and 8 genetically similar non-GM varieties 
of soybean. They used RAST-inhibition and basophil 
histamine release and found no significant difference 
between the GM and non-GM soybeans although there 
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were marked individual subject to subject and soybean 
line to soybean line differences.  My laboratory has 
also performed serum IgE binding studies on five 
different soybean events in total from three different 
commercial developers.  The methods used included 
GLUHFW ,J(ELQGLQJ(/,6$ LQKLELWLRQZLWK SRROHG
VR\EHDQDOOHUJLFVHUDRUGLUHFW(/,6$ZLWKLQGLYLGXDO
sera and found no significant differences in binding 
except between one or more of the non-GM lines[92,94]. 
Some differences were found in gain or loss of an IgE 
binding band in the qualitative IgE immunoblots in 
some non-GM soybeans. In addition to those standard 
methods for evaluating potential changes in allergen 
abundance, two-dimensional (2D) immunoblots were 
performed using individual sera to compare each GM 
to three non-GM soybean lines due to new regulatory 
demands by the EFSA[51] and EC regulations[52].  Some 
individual serum IgE binding spot differences were 
noted, but not showing specific changes for the GM 
lines[92,94]. Clearly the population of allergic subjects 
included in such studies will influence the outcome. 
It is impractical to include more than a few (10?) 
VSHFL¿FDOO\DOOHUJLFVXEMHFWVLQDVWXG\XQOHVVPXOWLSOH
large allergy centers are included.  There will always 
be some uncertainties regarding which proteins and 
isoforms might bind IgE from individual allergic 
subjects.  However, the suggestion by the EFSA to use 
SURWHRPLFV/&0606WRHYDOXDWHWKHDEXQGDQFHRI
individual “allergens” in soybeans and other commonly 
allergenic food crops is not as valid as serum testing 
because the list of “allergens” that EFSA wants to use 
[e.g. allergenic proteins in the OECD composition 
list for soybeans, includes proteins with little or no 
evidence of allergenicity (Gly m 1, Gly m 2, Gly m 3 
(profilin), P34 Gly m Bd 30 K, Unknown Asn-linked 
glycoprotein, lectin, lipoxygenase, Kunitze trypsin 
inhibitor, unknown 39 and 50 kD proteins and[22-25]. 
The important allergens in soybean that have been 
LGHQWLILHG LQFOXGH*O\P ȕFRQJO\FLQLQV DOSKD
alpha’- and beta-) and Gly m 6 (5-glycinins) and 
possibly Gly m 4, also known as SAM22.  Thus the 
EFSA recommendation is not based on evidence of 
risk since there is no gradation of risk in the proteins 
chosen and in fact some have no published evidence 
of allergy, or the protein sequence was not determined. 
,Q DGGLWLRQ /&0606 GRHV QRW SURYLGH 
coverage of any protein and it is therefore unlikely to 
identify isoforms, some of which may not bind IgE. 
Serum IgE binding tests at least compares a biological 
measurement between the GM and other non-GM 
varieties using sera from allergic subjects.   
However, it is important to consider whether there is 
relevance for safety to these measurements. Is there an 
increased risk of allergy if there is a difference?  People 
allergic to soybean should avoid eating any soybean. 
People who are not allergic can eat as much as they 
desire.  In processed foods the amount of total soybean 
protein can vary markedly from product to product and 
the food companies are not choosing lots of soybean 
based on specific varieties.  Instead they buy in bulk 
with the soybeans typically mixed at the silo, during 
shipment, in milling and processing and during food 
manufacture.
An important question that has not been answered 
E\DQ\VFLHQWL¿FVWXG\RUDQ\UHJXODWRU\ERG\LVZKDW
difference would be required in endogenous allergen 
accumulation to have an adverse impact on human 
health for the specifically food allergic subjects who 
are the sensitive, at-risk population?  An informative 
estimate might be made based on the dose-increase 
interval highly trained clinical food allergists use in 
performing double-blind placebo-controlled food 
challenges (DBPCFC).  There are a few publications 
describing protocols for testing high risk patients 
with the intent of establishing thresholds of doses 
for various allergens.  A review of studies by Crevel 
et al.[98] reported protocols with increasing challenge 
doses between 3-fold and 10-fold for peanuts with 
peanut allergic subjects. The experimental design for 
DBPCFC in the EuroPrevall studies began at three 
micrograms of protein from allergenic sources and 
used ten-fold increasing doses to 30 mg of protein, then 
reducing the step increase to three-fold above 30 mg as 
the risk of serious reactions were felt to increase above 
that dose[99]. Therefore it seems logical to conclude that 
at least a three-fold increase might of concern.
$VVHVVLQJSRWHQWLDOQHZXQLQWHQGHGSURWHLQV
During characterization of each new GM event 
the insertion of DNA is to be analyzed to confirm 
the sequence of the insert as well as the immediate 
surrounding DNA.  Typically a few hundred bases to 
a thousand bases are provided beyond the insert.  The 
sequence of the insert is to ensure that the protein(s) 
intended to be expressed (if any) are correct.  If an 
unexpected change has occurred, that should be 
evaluated in terms of the function of the new protein 
as well as possible risks for allergy and toxicity using 
bioinformatics.  The flanking DNA is considered to 
determine if there is a possibility a new fusion protein 
might be expressed in the plant.  All six potential 
reading frames in the DNA sequence are evaluated 
using computer algorithms to identify potential open 
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reading frames (ORF).  Some regulators are satisfied 
with start (methionine) to stop codons to define a 
potential ORF.  Others want all hypothetical ORFs 
meaning stop to stop.  The potential ORFs are then 
evaluated using bioinformatics to search for matches 
to allergens and toxins.  The critical segment is the 
fusion site. The plant DNA on each side of the insert 
was already there and if it encoded an allergen or toxin, 
those would have been endogenous hazards.  The 
safety assessment is focused on new potential hazards 
and risks. If there were matches to an allergen or a 
toxin, further analysis may be performed to evaluate 
whether and what tissues would transcribe RNA 
from that region of the DNA.  If the specific RNA is 
present, measurements could be made to determine if 
WKHUHLV WUDQVODWLRQSURGXFWSURWHLQXVLQJHLWKHU/&
MSMS or antibodies generated against a synthetic 
peptide “encoded” by the ORF in assays.  If there is a 
negligible level of protein, then the risk is minimal. 
Some regulators ask for flanking sequence until 
it is clear that the transgene has not interrupted an 
endogenous plant gene in the coding or intervening 
sequences (introns).  However evaluation of agronomic 
traits of the plants in field trials with geographical 
UHSOLFDWHVZLOOKHOSLGHQWLI\DQ\ELRORJLFDOO\VLJQL¿FDQW
differences of the GM vs non-GM varieties.  That type 
of evaluation is about performance of the plant, not 
safety.  The US regulators very interested in obtaining 
information relevant to safety of the food and feed 
products.  The GM developer and associated seed 
companies must show data to farmers to convince them 
that the GM plants produce adequately in terms of yield 
and overall composition.  Otherwise farmers will not 
purchase the seeds.
3.4  Assessing unintended effects conclusions
The conclusion of the compositional analysis is 
generally whether the total nutrients and anti-nutrients 
IRUWKHVSHFL¿FFURSDUHVXEVWDQWLDOO\HTXLYDOHQWWRQRQ
GM comparators or not. These analyses are performed 
using field-trial grown material of the GM and non-
GM varieties in geographical replicates.  Certainly 
there can be some statistically significant differences 
of measuring a number of components in many 
samples over different geographies will often result in 
a few statistically significant differences. Most of the 
variation is due to actual genetic differences that are 
associated with the whole plant genomes and back-
crossing and breeding programs and have nothing to 
do with transgene insertion[82-83].  In addition, recent 
discoveries that DNA methylation patterns can be 
inherited and alter gene expression without any change 
in DNA help us realize that we cannot expect to control 
or understand every measureable difference based on 
DNA sequence information[100].  And it is extremely 
important that we realize that every measurable 
difference does not constitute a risk for consumers, in 
fact very few do.  Humans selected and have improved 
most of the domesticated crops hundreds to thousands 
of years ago. We know that genetic variation is needed 
to be able to grow the same species in a wide variety of 
environmental conditions in order to produce food and 
feed.  
In the US the values from individual measurements 
are compared between the GM event and the near 
genetic relative (near isoline or parental variety) and 
also compared to either a number of commercial lines 
JURZQLQWKHVDPH¿HOGWULDOVRUUHFHQWKLVWRULFDOGDWD
from real production samples.  If the measures from 
the GM crop fall within the typical range of variation 
as a benchmark for potentially relevant biological 
differences, a difference between the GM and near 
genetic relative is considered acceptable.  The GM 
plant is therefore deemed “substantially equivalent” to 
other varieties of the crop.  Similar inferences are made 
from data obtained by measuring animal responses in 
feeding studies such as the 90-day rat feeding trial that 
VRPHUHJXODWRUVUHTXLUHGD\EURLOHUVWXGLHVRUODUJH
animal feeding trials that are generally used as industry 
acceptance studies in many countries, but are required 
in some (e.g. India).  
3.5  Current status of GMO approvals
How many GM events have been developed and 
gotten regulatory approvals for growing, of use as 
IRRGDQGIHHG",WLVKDUGWR¿QGDFFXUDWHLQIRUPDWLRQ
The Center for Environmental Risk Assessment 
&(5$*0 FURS GDWDEDVHZZZFHUDJPFRUJ
GmCropDatabase lists 153 total crop-events.  Not all 
of those were developed through GM technology as 
some were developed by mutagenesis or traditional 
breeding.  In addition, not all of those are approved 
anywhere and some are approved but not used.  The 
International Service for the Acquisition of Agri-
Biotech Applications (ISAAA) also maintains a GM 
FURSGDWDEDVH WKDW OLVWVHYHQWV ZZZLVDDDRUJ
gmapprovaldatabase).  By quick examination it seems 
ISAAA shows some crop types not listed by CERA 
including beans (Phaseolus vulgaris), eggplant or 
brinjal (Solanum melongea), poplar trees (Populus sp.), 
sugar cane (Saccharum sp.) and pepper (Capsicum 
annuum) that have not been submitted to U.S. or 
Canadian regulators.  It is likely that each of these 
databases misses a few events, but unlikely that either 
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of them miss globally traded GM crops. In addition 
the three US regulatory bodies each have a separate 
database that presents their actions on individual GM 
events.  The USDA website is: KWWSZZZDSKLVXVGD
JRYELRWHFKQRORJ\SHWLWLRQVBWDEOHBSHQGLQJVKWPO. The 
FDA website is: KWWSZZZDFFHVVGDWDIGDJRYVFULSWV
IGFF"VHW %LRFRQ. The EPA website is: KWWSZZZHSD
JRYRSSESSGELRSHVWLFLGHVSLSVSLSBOLVWKWP. 
Even though many events with different properties 
and in different plants are approved for use, the bulk of 
the GM events are in a few commodity crops (canola, 
cotton, maize, and soybean). The rate of adoption as 
measured in percent of hectares planted in GM crops 
in the U.S. has been extremely rapid, going from zero 
in 1994 to more than 90% of our soybeans and corn 
(maize) in 2014. A significant fraction of the cotton 
production in the U.S. is from GM events while 95% 
of cotton in India and 90% of cotton in China is GM 
cotton. There are now multiple events from different 
developers having similar functions (herbicide 
tolerance or specific insect resistance). At the same 
time a number of previously approved GM crops 
(post-1994) have disappeared from the market. Some 
products were dropped due to consumer or company 
pressures including the viral resistant, Colorado potato 
beetle resistant potatoes developed by Monsanto as 
major potato markets are dominated by French fry 
and fast food restaurants that are very sensitive to 
perceived consumer preferences.  Those products 
that dramatically reduced insecticide use on potatoes 
were withdrawn in about 2002 due to pressure from 
the fast food industry.  Herbicide tolerant wheat was 
submitted by Monsanto to Canada and the US, but 
was withdrawn before approval due to pressure from the 
Canadian Wheat Board because of fears export markets 
to Asia would block trade.   Delayed ripening tomatoes 
were dropped as they were not commercially viable (four 
companies including Zeneca and Monsanto had approved 
GM events) because fresh food qualities were not as good 
as non-GM varieties.  The viral resistant squash that was 
developed by Asgrow is still on the market, though now 
owned by Seminis. Viral resistant papaya was developed 
by researchers at Cornell University and was approved 
for use in the US because the Hawaiian trees were being 
decimated by ring spot virus.  The GM construct blocked 
replication of the virus and the introduction of this trait 
saved the industry in Hawaii.  
4  Summary
Some experts predict an eminent global food crisis 
while others suggest continuation of more regionalized 
crises that may be caused by local draught, disease 
or have artificial political or economic causes[101-102] 
%XWOHUD%XWOHUE 6RPHVROXWLRQV IRU
improving the global sustainable agriculture are 
and can be contributed through biotechnology, with 
current and future GM crops.  Yet progress is being 
VWLÀHGE\DYHU\IRFXVHGZHOO¿QDQFHGYRFDOPLQRULW\
of NGOs and by celebrities who are stirring public 
uncertainty even though they clearly do not have a 
good understanding of agriculture, food production 
DQGFRVWV&DQZH¿QGFRPPRQJURXQGLQWKLVGHEDWH"
Few who are students of food production, agriculture 
and human health would deny that at some point the 
world’s growing global population will outstrip the 
capacity to maintain food production in in the long-run 
HYHQWKRXJKWKHHI¿FLHQF\RISURGXFWLRQKDVLQFUHDVHG
markedly in the past century[103]. Yet our ability to 
increase production currently comes through the use of 
adding mined minerals, increased use of fossil fuels for 
fertilizer and tillage and the use of machines to replace 
human labor and draft animals in intensive agricultural 
practices.  Can we maintain our current rate of 
expansion? Experiences in the US agricultural system 
PD\SURYLGHXVHIXOH[DPSOHVIRU WKHSRWHQWLDOEHQH¿W
of GM crops in China and other Asian countries and in 
setting a standard for food safety of newly developed 
products.
In considering the experiences in the US regarding 
the safety evaluation process and regulations of 
genetically modified (GM) crops, it is necessary to 
look also at the global nature of food supplies, the 
concerns of various food safety regulatory bodies as 
well as consideration of the long history of various 
food crops. No country is self-sufficient and most 
foods consumed in any one country originally came 
from, or is dependent to some extent on inputs from 
other countries. The adaptation of wheat, rice, potatoes, 
tomatoes, peppers, various legumes and the specific 
animals we consume today were developed from 
naturally occurring ancestral organisms from very 
different geographical locations than those used for 
production today.  They were selected and improved 
through breeding processes that took hundreds or 
thousands of years.  They were chosen by experience, 
but based on food utility (nutritional and anti-
nutritional) characteristics, ease of production and 
food safety.  Yes there are real risks of foods for those 
with allergies and celiac disease. There are risks for 
those who do not prepare or store food properly to 
suppress microbes and spoilage and to inactivate anti-
5LFKDUG(*RRGPDQ%LRVDIHW\HYDOXDWLRQDQGUHJXODWLRQRI*HQHWLFDOO\0RGL¿HG*0 109
nutrients.  The primary potential risks of new proteins 
are relatively easy to prevent through the current 
assessment scheme.
There are a few uncertainties that US regulators are 
VWLOO¿QGLQJSHUSOH[LQJ3ULPDULO\LIWKHSURWHLQLVVWDEOH
in the pepsin assay, they are concerned that it might 
VHQVLWL]H DQGEHFRPHDQ DOOHUJHQ/RZDEXQGDQFH
VWDEOHSURWHLQVKDYHOLWWOHULVNDQGWKH\VKRXOG¿QGDQ
acceptance level.  We also need to continue working 
on a better way of predicting sensitization.  The 
current suggestions of computer programs to predict 
antigenicity are far from perfect and over-predict risk. 
$QLPDOPRGHOVVRIDUKDYHIDLOHGWRSURYLGHVXI¿FLHQWO\
accurate predictions to be useful.  Cell based assays 
using human antigen presenting cells, T cells and B 
cells have not been validated to demonstrate accurate 
predictions. Therefore additional research is needed for 
GLI¿FXOWSURWHLQVZKHUHWKHFXUUHQW&RGH[JXLGHOLQH[1] 
and US evaluation process do not show results leading 
to a conclusion of unlikely harm.  But most GM 
products today are easily cleared with bioinformatics 
for allergenicity, celiac disease and toxicity.  In a few 
cases serum IgE tests are needed and simple, predictive 
toxicity tests are needed.  
/DEHOLQJ RI IRRGV LV DPDMRU REVWDFOH DURXQG
the world.  Some countries like China have rules 
demanding labeling at least some foods if they contain 
GMOs.  In the US a few states have passed laws that 
may take effect in the near future and a few states 
will vote on labeling in November, 2014.  Major 
economic and practical food production hurdles make 
this approach untenable. Crops are grown and traded 
across state lines and national boundaries.  Food 
companies often make products for all 50 states and 
for export.  There are many individual ingredients that 
might contain a GMO, but that is not consistent from 
ORW WR ORW $VDQH[DPSOH¿JXUHVKRZVWKHODEHOHG
ingredients in a black vegetarian bean burger produced 
in the US.  Each component derived from soybeans, 
corn (maize), canola or cotton may be from a GMO. 
The CERA GM crop database (KWWSFHUDJPFRUJ
LQGH[SKS*0&URS'DWDEDVH) lists 12 approved GM 
soybeans representing 8 GM proteins and 57 approved 
maize lines representing at least 15 different proteins. 
Suppliers of commodities, ingredients and final food 
products would have to control and test for all of those 
ingredients if they do not want to list “GMO” on the 
label if these laws pass.  There will be added expense, 
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and no safety benefit.  For foods that are already 
cluttered with labeled information, critical safety 
information such as allergen content gets lost.  
The foods humans consume are tremendously 
diverse in composition, nutritional qualities and to 
some extent, risks.  We are omnivores and our ancestors 
adapted to many different climates and conditions 
as they spread across continents and changed from 
migratory hunter-gatherers to migratory pastoralists 
and then to relatively sedentary agriculturalists[104,106]. 
The adaptations seem to have been possible because 
of the ability of humans to cooperate and accept added 
costs of helping to ensure survival of others rather 
than protection of the immediate family, an adaptation 
that was not always beneficial to the immediate 
relatives, but was beneficial for the society[106]. In 
the post-industrial era humans have become highly 
mobile individually.  However, within each society 
the basic food production infrastructure needed to 
maintain the population is slow to change for many 
reasons including the large investment in equipment, 
complexity of the commodity and food processing 
facilities and the relatively restricted genetic pool of 
plants and animals that are used for production.  But 
adaptation occurs and the efficiency of production 
has increased, especially during the last century. 
Increased have occurred even as land is available 
for farming as the population concentrated in cities 
away from the production of food crops[107].  Since 
the world population is now estimated to be over 7.25 
billion people, and with a total biomass exceeding the 
combined total of all other terrestrial vertebrates we 
need to think hard about how to improve food and feed 
production.  It took hundreds or thousands of years to 
learn how to manage and accept many new methods of 
food production. In the past 100 years food production 
has shifted markedly to more industrialized methods to 
meet food demands.  Some people would seek to stop 
the technology, restrict the tools of introducing new 
improvements into food crops because of claims they 
produce unsafe foods.  But as I search for evidence of 
harm from GM crops, it is not there.
It is helpful to consider that none of the plant foods 
that we grow and consume today are completely natural. 
Although they are genetically fairly similar to some 
native plants, the grains (wheat, barley, rye, rice, maize, 
sorghum) have been bred and selected for hundreds of 
years.  Many varieties of tomatoes, potatoes, eggplant 
and peppers are quite safe for consumption after many 
forms of cooking and processing.  But they are closely 
related, in the same plant family (Solanaceae) as toxic 
nightshade, which along with tobacco and petunias 
are really not edible.  The edible solanaceous plants 
have wild relatives in the same species that produce 
sufficient levels of glycoalkaloids (solanine, tomatine 
and others) and lectins that are quite harmful to us and 
to many domestic animals if consumed.  We can only 
consume the current varieties of these crops because 
our ancestors went through a process of breeding and 
selecting varieties with low levels of these toxins and 
anti-nutrients in the edible plant parts.  They did that 
ZLWKRXWWKHFRPSOH[VFLHQWL¿FWHVWVDQGLQVWUXPHQWVZH
XVHWRGD\WRGHWHFWVSHFL¿FVXEVWDQFHVWKDWFDXVHKDUP
They did that without having standardized animal 
feeding trials. Even though we are omnivores and can 
consume many different plants and animals, we have 
had to learn the limits of what we can consume.  And 
even though the potatoes that we eat today are safe, 
we have learned that some wild relatives produce 
VXI¿FLHQWO\KLJKFRQFHQWUDWLRQVRIDVRODQLQHWRPDWLQH
and other glycoalkaloids to cause harm or even death.
Beyond a historical perspective, it is also important 
to remember that we live in an age of increasing 
information distribution with frequent unintended 
impacts of miss-information. There are many claims of 
real or potential harm from various foods that would 
never have been noticed centuries or event decades 
ago, but often the communicated fears are hypothetical 
risks.  However, instant messaging and the internet 
compress years to seconds.  When European explorers 
brought tomatoes and potatoes from South America to 
Italy and the United Kingdom in the 1500’s they were 
introducing crops that had been grown and consumed 
safely for over a thousand years.  But in Europe people 
did not have full knowledge of how to grow and use 
the plants.  Some who became ill due to improper food 
preparation or eating the green part of the plants and 
after falling ill people suggested that the entire plants 
were poisonous including the fruits and tubers.  Natives 
of South American knew to avoid consuming the green 
plant material.  The rare cases of harm in Europe lead 
to wide spread fear that stifled the introduction of 
these now staple foods into the European diets.  Now 
false claims about GMOs are common and effects 
long lasting.  Recent claims by Dr. Oz, Jeffrey Smith, 
Oprah Winfrey or Cui Yongyuan claim that GM 
crops are unsafe or untested have caused consumers 
to become skeptical of claims by biotechnology 
companies and governments that they are safe. Those 
media personalities however have not read the dossiers 
or performed safety studies that have convinced US 
regulators the products like European Corn Borer 
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resistant MON810 is safe.  How do we present the truth 
to consumers when there are “trusted” personalities 
telling consumers that the government is corrupt and 
that big biotech companies like Monsanto did not do an 
adequate job of testing and evaluating safety? 
5  Conclusions
The US regulatory system for evaluating the safety of 
GM crops involves three federal agencies, the USDA, 
the FDA and EPA. The process for evaluation was 
initiated in the late 1980s and early 1990s through 
consultations that included academics, industry 
scientists and governmental regulatory scientists 
and policy makers. The assessment was refined in 
the late 1990s through 2003 and aligned with the 
Codex Alimentarius Commission Guidelines for the 
safety assessment of GM crops.  Potential risks of 
allergenicity of foods produced from the GM crops 
must be evaluated using scientifically acceptable 
methods.  The process is efficient for identifying 
proteins that are likely to present a significant risk of 
food allergy, which would be the transfer of a known 
allergen or a likely cross-reactive protein. There is 
a bit less certainty trying to predict whether a new 
protein with no obvious risks factors might sensitize 
de novo, but risks are clearly low in those cases where 
the protein is rapidly digested by pepsin in a test-tube 
DVVD\DQGRUORZLQDEXQGDQFHLQWKHIRRGFRPSRQHQW
7KHSRWHQWLDOWKDWDWUDQVJHQLFKDVVLJQL¿FDQWO\KLJKHU
expression of endogenous allergens is quite low 
compared to non-GM varieties, but in addition the 
risk is for those consumers who should be avoiding 
consumption of food from the host plant anyway. Thus 
there is no practical increase in risk even if the content 
of endogenous allergens was increased.  Potential 
food toxicity is also evaluated based on criteria 
established for non-GMOs.  Few proteins are toxic 
and the comparison of the sequence of the GM protein 
to those of known toxins along with evaluation of the 
gene source and the mechanism of action of the protein 
will identify high risk proteins.  The US has evaluated 
and approved the commercialization of approximately 
100 new events or varieties of GMO.  There are no 
documented cases where an approved GM crop has 
caused harm to humans or animals who have consumed 
edible parts of the plants.  However, the regulatory 
process is expensive and time consuming. Since most 
food crops are traded on an international market, it is 
unfortunate that there isn’t a single safety evaluation 
process that is standardized and accepted across all 
countries to avoid duplication of studies.   
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